4D MOLECULAR THERAPEUTICS, INC.35104E100US35104E100106/17/2026Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. Nancy Miller-RichDIRECTOR ELECTIONSISSUER114910FOR11491FOR19 4D MOLECULAR THERAPEUTICS, INC.35104E100US35104E100106/17/2026Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. John F. Milligan, Ph.D.DIRECTOR ELECTIONSISSUER114910FOR11491FOR19 4D MOLECULAR THERAPEUTICS, INC.35104E100US35104E100106/17/2026Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. Shawn Cline Tomasello, MBADIRECTOR ELECTIONSISSUER114910FOR11491FOR19 4D MOLECULAR THERAPEUTICS, INC.35104E100US35104E100106/17/2026Ratification of the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER114910FOR11491FOR19 4D MOLECULAR THERAPEUTICS, INC.35104E100US35104E100106/17/2026Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers (''say-on-pay vote'').SECTION 14A SAY-ON-PAY VOTESISSUER114910FOR11491FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Election of Class II Directors Jennifer L. DavisDIRECTOR ELECTIONSISSUER964200FOR96420FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Election of Class II Directors Melody B. MeyerDIRECTOR ELECTIONSISSUER964200FOR96420FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Election of Class II Directors Robert A. MichaelDIRECTOR ELECTIONSISSUER964200FOR96420FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Election of Class II Directors Frederick H. WaddellDIRECTOR ELECTIONSISSUER964200FOR96420FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2026AUDIT-RELATEDISSUER964200FOR96420FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Say on Pay - An advisory vote on the approval of executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER964200FOR96420FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority votingSHAREHOLDER RIGHTS AND DEFENSESISSUER964200FOR96420FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Stockholder Proposal - to Adopt a Policy to Require an Independent ChairCORPORATE GOVERNANCESECURITY HOLDER964200AGAINST96420FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Judy Gawlik BrownDIRECTOR ELECTIONSISSUER347240FOR34724FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Sue H. RatajDIRECTOR ELECTIONSISSUER347240FOR34724FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: George A. Scangos, Ph.D.DIRECTOR ELECTIONSISSUER347240FOR34724FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Dow R. WilsonDIRECTOR ELECTIONSISSUER347240FOR34724FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER347240FOR34724FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026To ratify the Audit and Finance Committee's appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm.AUDIT-RELATEDISSUER347240FOR34724FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026To approve an amendment to Agilent's Third Amended and Restated Certificate of Incorporation to declassify the Board of Directors over a three-year period.SHAREHOLDER RIGHTS AND DEFENSESISSUER347240FOR34724FOR19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified. Rahul Ballal, Ph.D.DIRECTOR ELECTIONSISSUER302450FOR30245FOR19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified. Brian GoffDIRECTOR ELECTIONSISSUER302450FOR30245FOR19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified. Cynthia SmithDIRECTOR ELECTIONSISSUER302450WITHHOLD30245AGAINST19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER302450FOR30245FOR19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To approve an amendment to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan, as Amended, to increase the number of shares of common stock available thereunder by 2,000,000 shares.COMPENSATIONISSUER302450FOR30245FOR19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER302450FOR30245FOR19 ALCON INC.H01301128CH043249246704/30/2026Approval of the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2025CORPORATE GOVERNANCEISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Discharge of the members of the Board of Directors and the members of the Executive CommitteeDIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Appropriation of earnings and declaration of dividend as per the balance sheet of Alcon Inc. of December 31, 2025CAPITAL STRUCTUREISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Consultative vote on the 2025 Report on Non-Financial MattersOTHER SOCIAL ISSUESISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Consultative vote on the 2025 Compensation ReportSECTION 14A SAY-ON-PAY VOTESISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Binding vote on the maximum aggregate amount of compensation of the Board of Directors for the next term of office, i.e. from the 2026 Annual General Meeting to the 2027 Annual General MeetingCOMPENSATIONISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Binding vote on the maximum aggregate amount of compensation of the Executive Committee for the following financial year, i.e. 2027COMPENSATIONISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of F. Michael Ball (as Member and Chair)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Lynn D. Bleil (as Member)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Arthur Cummings (as Member)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Deborah Di Sanzo (as Member)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of David J. Endicott (as Member)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Thomas Glanzmann (as Member)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of D. Keith Grossman (as Member)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Karen May (as Member)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Ines Pöschel (as Member)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Dieter Spälti (as Member)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Election of R. Scott Herren (as Member)DIRECTOR ELECTIONSISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Thomas Glanzmann as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Karen May as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Ines Pöschel as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of the independent representative, Hartmann Dreyer, Attorneys-at-lawCORPORATE GOVERNANCEISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of the statutory auditors, PricewaterhouseCoopers SA, GenevaAUDIT-RELATEDISSUER57510FOR5751FOR19 ALCON INC.H01301128CH043249246704/30/2026General instruction in case of new agenda items or proposals put forth during the Annual General Meeting (please check one box only) * If you vote FOR, you will be voting in accordance with the recommendation of the Board of Directors. ** If you vote AGAINST, you will be voting against the new agenda items or proposals. *** If you vote ABSTAIN, you will abstain from voting.CORPORATE GOVERNANCEISSUER57510ABSTAIN5751AGAINST19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026Election of Directors Deborah MessemerDIRECTOR ELECTIONSISSUER1054650FOR105465FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026Election of Directors Vicki Sato, Ph.D.DIRECTOR ELECTIONSISSUER1054650FOR105465FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026Election of Directors Owen Witte, M.D.DIRECTOR ELECTIONSISSUER1054650FOR105465FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1054650FOR105465FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER10546501 YEAR105465FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000 shares.CAPITAL STRUCTUREISSUER1054650FOR105465FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1054650FOR105465FOR19 ALNYLAM PHARMACEUTICALS, INC.02043Q107US02043Q107605/20/2026To elect the following nominees as Class I directors of Alnylam: Stuart A. ArbuckleDIRECTOR ELECTIONSISSUER83780FOR8378FOR19 ALNYLAM PHARMACEUTICALS, INC.02043Q107US02043Q107605/20/2026To elect the following nominees as Class I directors of Alnylam: Yvonne L. Greenstreet, M.D.DIRECTOR ELECTIONSISSUER83780FOR8378FOR19 ALNYLAM PHARMACEUTICALS, INC.02043Q107US02043Q107605/20/2026To elect the following nominees as Class I directors of Alnylam: Elliott Sigal, M.D., Ph.D.DIRECTOR ELECTIONSISSUER83780FOR8378FOR19 ALNYLAM PHARMACEUTICALS, INC.02043Q107US02043Q107605/20/2026To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER83780FOR8378FOR19 ALNYLAM PHARMACEUTICALS, INC.02043Q107US02043Q107605/20/2026To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER83780FOR8378FOR19 ALUMIS INC022307102US022307102006/30/2026DIRECTOR: James B. TananbaumDIRECTOR ELECTIONSISSUER257950FOR25795FOR19 ALUMIS INC022307102US022307102006/30/2026DIRECTOR: Lynn Tetrault, J.D.DIRECTOR ELECTIONSISSUER257950FOR25795FOR19 ALUMIS INC022307102US022307102006/30/2026DIRECTOR: Zhengbin Yao, Ph.D.DIRECTOR ELECTIONSISSUER257950ABSTAIN25795AGAINST19 ALUMIS INC022307102US022307102006/30/2026To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for the Company's fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER257950FOR25795FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Wanda M. AustinDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. BradwayDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Michael V. DrakeDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Brian J. DrukerDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. EckertDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Greg C. GarlandDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Charles M. Holley, Jr.DIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. S. Omar IshrakDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Tyler JacksDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Mary E. KlotmanDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Ellen J. KullmanDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Amy E. MilesDIRECTOR ELECTIONSISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026Advisory vote to approve our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER208610FOR20861FOR19 AMGEN INC.031162100US031162100905/19/2026Stockholder proposal to require an independent board chairman.CORPORATE GOVERNANCESECURITY HOLDER208610AGAINST20861FOR19 APOGEE THERAPEUTICS, INC.03770N101US03770N101906/09/2026DIRECTOR: Mark C. McKennaDIRECTOR ELECTIONSISSUER177800FOR17780FOR19 APOGEE THERAPEUTICS, INC.03770N101US03770N101906/09/2026DIRECTOR: Jennifer FoxDIRECTOR ELECTIONSISSUER177800FOR17780FOR19 APOGEE THERAPEUTICS, INC.03770N101US03770N101906/09/2026DIRECTOR: William (BJ) Jones, Jr.DIRECTOR ELECTIONSISSUER177800FOR17780FOR19 APOGEE THERAPEUTICS, INC.03770N101US03770N101906/09/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER177800FOR17780FOR19 APOGEE THERAPEUTICS, INC.03770N101US03770N101906/09/2026Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER177800FOR17780FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026Election of Directors. Dietmar Berger, M.D., Ph.D.DIRECTOR ELECTIONSISSUER396540FOR39654FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026Election of Directors. David Lacey, M.D.DIRECTOR ELECTIONSISSUER396540FOR39654FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026Election of Directors. Nicole LambertDIRECTOR ELECTIONSISSUER396540FOR39654FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026Election of Directors. Johanna MercierDIRECTOR ELECTIONSISSUER396540FOR39654FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of Arcus Biosciences for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER396540FOR39654FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER396540FOR39654FOR19 ARGENX SE04016X101US04016X101911/18/2025Proposal to adopt the remuneration policy.SECTION 14A SAY-ON-PAY VOTESISSUER57630FOR5763FOR19 ARGENX SE04016X101US04016X101905/06/2026The 2025 remuneration report (advisory non-binding voting item)SECTION 14A SAY-ON-PAY VOTESISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Adoption of the 2025 annual accounts (voting item)CORPORATE GOVERNANCEISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Allocation of profits of the Company in the financial year 2025 to the retained earnings of the Company (voting item)CAPITAL STRUCTUREISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Proposal to release the executive director of the Board from liability for his duties carried out in the financial year 2025 (voting item)DIRECTOR ELECTIONSISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Proposal to release the non-executive directors of the Board from liability for their respective duties carried out in the financial year 2025 (voting item)DIRECTOR ELECTIONSISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Appointment of Karen Massey as executive director to the Board, for a four-year term (voting item)DIRECTOR ELECTIONSISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Appointment of Tim Van Hauwermeiren as non-executive director to the Board, for a four-year term (voting item)DIRECTOR ELECTIONSISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Reappointment of Ana Céspedes as non-executive director to the Board, for a four-year term (voting item)DIRECTOR ELECTIONSISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Reappointment of Camilla Sylvest as non-executive director to the Board, for a four-year term (voting item)DIRECTOR ELECTIONSISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Reappointment of Pamela Klein as non-executive director to the Board, for a two-year term (voting item)DIRECTOR ELECTIONSISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of the Company up to a maximum of 10% of the outstanding capital at the date of the general meeting for a period of 18 months from the general meeting and to limit or exclude statutory pre-emptive rights (voting item)CAPITAL STRUCTUREISSUER96371000FOR9637FOR19 ARGENX SE04016X101US04016X101905/06/2026Appointment of Ernst & Young Accountants LLP as external auditor of the Company for the 2026 financial year (voting item)AUDIT-RELATEDISSUER96371000FOR9637FOR19 ASTRAZENECA PLCG0593M107GB000989529211/03/2025Adopt New Articles of AssociationCORPORATE GOVERNANCEISSUER324760FOR32476FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Approve DividendsCAPITAL STRUCTUREISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Appoint KPMG LLP as AuditorsAUDIT-RELATEDISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Authorise Board to Fix Remuneration of AuditorsAUDIT-RELATEDISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Michel Demare as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Pascal Soriot as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Aradhana Sarin as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Philip Broadley as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Euan Ashley as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Birgit Conix as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Rene Haas as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Karen Knudsen as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Diana Layfield as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Anna Manz as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Sheri McCoy as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Tony Mok as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Re-elect Marcus Wallenberg as DirectorDIRECTOR ELECTIONSISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Approve Remuneration ReportSECTION 14A SAY-ON-PAY VOTESISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Amend Performance Share PlanCOMPENSATIONISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Authorise UK Political Donations and ExpenditureOTHER SOCIAL ISSUESISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Authorise Issue of EquityCAPITAL STRUCTUREISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Authorise Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital InvestmentCAPITAL STRUCTUREISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Authorise Market Purchase of Ordinary SharesCAPITAL STRUCTUREISSUER338420FOR33842FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Authorise the Company to Call General Meeting with Two Weeks' NoticeSHAREHOLDER RIGHTS AND DEFENSESISSUER338420FOR33842FOR19 AVIDITY BIOSCIENCES, INC.05370A108US05370A108802/26/2026To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Novartis"), Ajax Acquisition Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis, and Avidity Biosciences, Inc., a Delaware corporation (the "Company"), and (ii) the Separation and Distribution Agreement, dated as of October 25, 2025 (the "Separation Agreement"), among the Company, Bryce Therapeutics, Inc., a newly formed Delaware corporation and wholly owned subsidiary of the Company, and which on December 8, 2025, changed its name to Atrium Therapeutics, Inc., and Novartis (with respect to certain sections therein).EXTRAORDINARY TRANSACTIONSISSUER87320FOR8732FOR19 AVIDITY BIOSCIENCES, INC.05370A108US05370A108802/26/2026To adjourn the Special Meeting, if necessary, desirable or appropriate or to solicit additional proxies if, at the time of the Special Meeting, there are an insufficient number of votes in favor of adopting the Merger Agreement and the Separation Agreement.CORPORATE GOVERNANCEISSUER87320FOR8732FOR19 AVIDITY BIOSCIENCES, INC.05370A108US05370A108802/26/2026To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement.SECTION 14A SAY-ON-PAY VOTESISSUER87320FOR8732FOR19 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. John EvansDIRECTOR ELECTIONSISSUER146110FOR14611FOR19 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. John Maraganore, Ph.D.DIRECTOR ELECTIONSISSUER146110FOR14611FOR19 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. Christi ShawDIRECTOR ELECTIONSISSUER146110FOR14611FOR19 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER146110FOR14611FOR19 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER146110FOR14611FOR19 BICARA THERAPEUTICS INC.055477103US055477103206/09/2026To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Christopher Bowden, M.D.DIRECTOR ELECTIONSISSUER141440FOR14144FOR19 BICARA THERAPEUTICS INC.055477103US055477103206/09/2026To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Carolyn Ng, Ph.D.DIRECTOR ELECTIONSISSUER141440FOR14144FOR19 BICARA THERAPEUTICS INC.055477103US055477103206/09/2026To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER141440FOR14144FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025To set the number of Directors at nine.CORPORATE GOVERNANCEISSUER175180FOR17518FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Robert V. BaumgartnerDIRECTOR ELECTIONSISSUER175180FOR17518FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Julie L. BushmanDIRECTOR ELECTIONSISSUER175180FOR17518FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Judith KlimovskyDIRECTOR ELECTIONSISSUER175180FOR17518FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors John L. HigginsDIRECTOR ELECTIONSISSUER175180FOR17518FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Kim KeldermanDIRECTOR ELECTIONSISSUER175180FOR17518FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Alpna SethDIRECTOR ELECTIONSISSUER175180FOR17518FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Rupert VesseyDIRECTOR ELECTIONSISSUER175180FOR17518FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Joseph D. KeeganDIRECTOR ELECTIONSISSUER175180FOR17518FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Amy HerrDIRECTOR ELECTIONSISSUER175180FOR17518FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Approve, on an advisory basis, the compensation of our executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER175180AGAINST17518AGAINST19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Ratify the appointment of KPMG, LLP as the Company's independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER175180FOR17518FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Maria C. FreireDIRECTOR ELECTIONSISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. William A. HawkinsDIRECTOR ELECTIONSISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Susan K. LangerDIRECTOR ELECTIONSISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Jesus B. MantasDIRECTOR ELECTIONSISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Lloyd MinorDIRECTOR ELECTIONSISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Menelas PangalosDIRECTOR ELECTIONSISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Monish PatolawalaDIRECTOR ELECTIONSISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Eric K. RowinskyDIRECTOR ELECTIONSISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Stephen A. SherwinDIRECTOR ELECTIONSISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Christopher A. ViehbacherDIRECTOR ELECTIONSISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER318690FOR31869FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Say on Pay - To hold an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER318690FOR31869FOR19 BIOHAVEN LTDG1110E107VGG1110E107904/28/2026Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Michael T. HeffernanDIRECTOR ELECTIONSISSUER304690FOR30469FOR19 BIOHAVEN LTDG1110E107VGG1110E107904/28/2026Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Irina Antonijevic, M.D., Ph.D.DIRECTOR ELECTIONSISSUER304690FOR30469FOR19 BIOHAVEN LTDG1110E107VGG1110E107904/28/2026Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Robert J. HuginDIRECTOR ELECTIONSISSUER304690FOR30469FOR19 BIOHAVEN LTDG1110E107VGG1110E107904/28/2026Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2026.AUDIT-RELATEDISSUER304690FOR30469FOR19 BIOHAVEN LTDG1110E107VGG1110E107904/28/2026A non-binding advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER304690FOR30469FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Elizabeth M. AndersonDIRECTOR ELECTIONSISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Barbara W. BodemDIRECTOR ELECTIONSISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Ian T. ClarkDIRECTOR ELECTIONSISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Athena CountouriotisDIRECTOR ELECTIONSISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Willard DereDIRECTOR ELECTIONSISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Mark J. EnyedyDIRECTOR ELECTIONSISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Alexander HardyDIRECTOR ELECTIONSISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Maykin HoDIRECTOR ELECTIONSISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Robert J. HombachDIRECTOR ELECTIONSISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Timothy P. WalbertDIRECTOR ELECTIONSISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER295770FOR29577FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.COMPENSATIONISSUER295770FOR29577FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the appropriation of the balance sheet profit for the 2025 financial yearCAPITAL STRUCTUREISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the approval of the actions of the Management BoardDIRECTOR ELECTIONSISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the approval of the actions of the Supervisory BoardDIRECTOR ELECTIONSISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the appointment of the auditor and the Group auditor for the 2026 financial year and the auditor for any audit or review of interim reportsAUDIT-RELATEDISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the approval of the Compensation ReportSECTION 14A SAY-ON-PAY VOTESISSUER36950AGAINST3695AGAINST19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the amendment of Section 9 para. 1 of the Articles of Association to increase the size of the Supervisory BoardDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Elections to the Supervisory Board: Mr. Helmut JeggleDIRECTOR ELECTIONSISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Elections to the Supervisory Board: Prof. Dr. Anja MorawietzDIRECTOR ELECTIONSISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Elections to the Supervisory Board: Prof. Dr. Rudolf StaudiglDIRECTOR ELECTIONSISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Elections to the Supervisory Board: Dr. Susanne SchaffertDIRECTOR ELECTIONSISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Elections to the Supervisory Board: Prof. Dr. Iris Loew-FriedrichDIRECTOR ELECTIONSISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the amendment of Section 16 para. 5 of the Articles of Association to reauthorize the Management Board to provide for the holding of a virtual Annual General MeetingCORPORATE GOVERNANCEISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the cancellation of the existing Authorized Capital 2025 and the creation of new Authorized Capital 2026 with the possibility of excluding subscription rights and corresponding amendment to the Articles of AssociationCAPITAL STRUCTUREISSUER36950FOR3695FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the approval of the conclusion of a domination and profit and loss transfer agreement between BioNTech SE and BioNTech Discovery GmbHEXTRAORDINARY TRANSACTIONSISSUER36950FOR3695FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. David C. HabigerDIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Edward J. LudwigDIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Michael F. MahoneyDIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Jessica L. MegaDIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Susan E. MoranoDIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Cheryl PegusDIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Cathy R. SmithDIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Christophe P. WeberDIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. David S. WichmannDIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Ellen M. ZaneDIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To amend our Employee Stock Purchase Plan to increase the number of shares reserved for issuance.COMPENSATIONISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To amend our Certificate of Incorporation to remove supermajority voting provisions.SHAREHOLDER RIGHTS AND DEFENSESISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To amend our Certificate of Incorporation to provide for exculpation of certain officers as permitted by Delaware law.DIRECTOR ELECTIONSISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To amend our Certificate of Incorporation and By-Laws to permit stockholders holding 25% of our common stock to call a special meeting of stockholders.SHAREHOLDER RIGHTS AND DEFENSESISSUER1016480FOR101648FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting."SHAREHOLDER RIGHTS AND DEFENSESCORPORATE GOVERNANCESECURITY HOLDER1016480AGAINST101648FOR19 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.107924102US107924102206/16/2026To elect two Class I directors to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Frank McCormick, Ph.D., F.R.S., D.Sc.DIRECTOR ELECTIONSISSUER600300FOR60030FOR19 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.107924102US107924102206/16/2026To elect two Class I directors to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Peter Lebowitz, M.D., Ph.D.DIRECTOR ELECTIONSISSUER600300FOR60030FOR19 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.107924102US107924102206/16/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER600300FOR60030FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026DIRECTOR: James C. MomtazeeDIRECTOR ELECTIONSISSUER180550FOR18055FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026DIRECTOR: Frank P. McCormick, PhDDIRECTOR ELECTIONSISSUER180550FOR18055FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026DIRECTOR: Hannah A. Valantine, MDDIRECTOR ELECTIONSISSUER180550FOR18055FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER180550FOR18055FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1805501 YEAR18055FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER180550FOR18055FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares.COMPENSATIONISSUER180550FOR18055FOR19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: Ian McDonaldDIRECTOR ELECTIONSISSUER83680FOR8368FOR19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: Nils BottlerDIRECTOR ELECTIONSISSUER83680ABSTAIN8368AGAINST19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: Jeremy FryzukDIRECTOR ELECTIONSISSUER83680ABSTAIN8368AGAINST19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: Jan PedersenDIRECTOR ELECTIONSISSUER83680ABSTAIN8368AGAINST19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: David WeinerDIRECTOR ELECTIONSISSUER83680ABSTAIN8368AGAINST19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: Steve FarrDIRECTOR ELECTIONSISSUER83680FOR8368FOR19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026Appointment of DeVisser Gray LLP, Chartered Professional Accountants, as Auditors of the Company for the ensuing year and authorizing the Directors to fix their remuneration.AUDIT-RELATEDCOMPENSATIONISSUER83680FOR8368FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Peter J. ArduiniDIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Deepak L. Bhatt, M.D., M.P.H., M.B.A.DIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Christopher S. Boerner, Ph.D.DIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Julia A. Haller, M.D.DIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Manuel Hidalgo Medina, M.D., Ph.D.DIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Michael R. McMullenDIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Paula A. PriceDIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Derica W. RiceDIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Theodore R. SamuelsDIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Karen H. Vousden, Ph.D.DIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Phyllis R. YaleDIRECTOR ELECTIONSISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Advisory Vote to Approve the Compensation of our Named Executive OfficersSECTION 14A SAY-ON-PAY VOTESISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Vote to Approve the Company's 2026 Stock Award and Incentive PlanCOMPENSATIONISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Ratification of the Appointment of an Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER962590FOR96259FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent DirectorCORPORATE GOVERNANCESECURITY HOLDER962590AGAINST96259FOR19 BRUKER CORPORATION116794108US116794108705/21/2026DIRECTOR: John J. (Jack) PhillipsDIRECTOR ELECTIONSISSUER433070FOR43307FOR19 BRUKER CORPORATION116794108US116794108705/21/2026DIRECTOR: Hermann F. Requardt PhDDIRECTOR ELECTIONSISSUER433070FOR43307FOR19 BRUKER CORPORATION116794108US116794108705/21/2026DIRECTOR: Laura A. FrancisDIRECTOR ELECTIONSISSUER433070FOR43307FOR19 BRUKER CORPORATION116794108US116794108705/21/2026Approval on an advisory basis of the 2025 compensation of our named executive officers, as discussed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER433070FOR43307FOR19 BRUKER CORPORATION116794108US116794108705/21/2026Ratification of the appointment of PricewaterhouseCoopers LLP as our Independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER433070FOR43307FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Werner BaumannDIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Frank K. ClyburnDIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Ellen G. CooperDIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. D. Mark DurcanDIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Lon R. GreenbergDIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Lorence H. Kim, M.D.DIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Robert P. MauchDIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Redonda G. Miller, M.D.DIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Dennis M. NallyDIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Lori J. RyerkerkDIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Lauren M. TylerDIRECTOR ELECTIONSISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Advisory vote to approve the fiscal 2025 compensation of Cencora, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER206870FOR20687FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Ratify the appointment of Ernst & Young LLP as Cencora, Inc.'s independent registered public accounting firm for fiscal 2026.AUDIT-RELATEDISSUER206870FOR20687FOR19 CG ONCOLOGY, INC.156944100US156944100906/04/2026To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. Christina RossiDIRECTOR ELECTIONSISSUER50950FOR5095FOR19 CG ONCOLOGY, INC.156944100US156944100906/04/2026To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. Victor Tong, Jr.DIRECTOR ELECTIONSISSUER50950FOR5095FOR19 CG ONCOLOGY, INC.156944100US156944100906/04/2026To ratify the appointment by the Audit Committee of the Board of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER50950FOR5095FOR19 CG ONCOLOGY, INC.156944100US156944100906/04/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER50950FOR5095FOR19 CG ONCOLOGY, INC.156944100US156944100906/04/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER509501 YEAR5095FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Nancy C. AndrewsDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Steven BargDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Abraham CeesayDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Mark EnyedyDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: James C. FosterDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Birgit GirshickDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Paul GravesDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Reshema Kemps-PolancoDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: George LladoDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Martin MackayDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Craig B. ThompsonDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Virginia WilsonDIRECTOR ELECTIONSISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Advisory Approval of 2025 Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/20262026 Long-Term Incentive PlanCOMPENSATIONISSUER49360FOR4936FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Ratification of Pricewaterhousecoopers LLC as independent registered public accounting firm for 2026AUDIT-RELATEDISSUER49360FOR4936FOR19 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026DIRECTOR: Dr. Chris CainDIRECTOR ELECTIONSISSUER1246420FOR124642FOR19 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026DIRECTOR: Arlene M. MorrisDIRECTOR ELECTIONSISSUER1246420FOR124642FOR19 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026DIRECTOR: Todd ShegogDIRECTOR ELECTIONSISSUER1246420FOR124642FOR19 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER1246420FOR124642FOR19 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1246420FOR124642FOR19 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders: Richard A. Miller, M.DDIRECTOR ELECTIONSISSUER96890FOR9689FOR19 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders: Linda S. Grais, M.D. J.DDIRECTOR ELECTIONSISSUER96890WITHHOLD9689AGAINST19 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER96890FOR9689FOR19 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER96890FOR9689FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors Fernando AguirreDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors Jeffrey R. Balser, M.D., Ph.D.DIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors C. David Brown IIDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors Alecia A. DeCoudreauxDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors Anne M. FinucaneDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors John E. GallinaDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors J. David JoynerDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors J. Scott KirbyDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors Michael F. MahoneyDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors Leslie V. NorwalkDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors Larry M. RobbinsDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors Guy P. SansoneDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Election of Directors Douglas H. ShulmanDIRECTOR ELECTIONSISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Ratification of the Appointment of Our Independent Registered Public Accounting Firm for 2026.AUDIT-RELATEDISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Say on Pay, a Proposal to Approve, on an Advisory Basis, the Company's Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Proposal to Approve the Company's 2026 Incentive Compensation Plan.COMPENSATIONISSUER317710FOR31771FOR19 CVS HEALTH CORPORATION126650100US126650100605/14/2026Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent.SHAREHOLDER RIGHTS AND DEFENSESSECURITY HOLDER317710AGAINST31771FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026Election of Class I Directors for terms expiring in 2029. Edward M. Kaye, M.D.DIRECTOR ELECTIONSISSUER162550FOR16255FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026Election of Class I Directors for terms expiring in 2029. Wendell Wierenga, Ph.D.DIRECTOR ELECTIONSISSUER162550FOR16255FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026Election of Class I Directors for terms expiring in 2029. Nancy J. WysenskiDIRECTOR ELECTIONSISSUER162550FOR16255FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance thereunder by 1,000,000 shares of common stock.COMPENSATIONISSUER162550FOR16255FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER162550FOR16255FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER162550FOR16255FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Approve Appropriation of SurplusCAPITAL STRUCTUREISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Okuzawa, HiroyukiDIRECTOR ELECTIONSISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Matsumoto, TakashiDIRECTOR ELECTIONSISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Ueno, ShizukoDIRECTOR ELECTIONSISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Joseph Kenneth KellerDIRECTOR ELECTIONSISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Komatsu, YasuhiroDIRECTOR ELECTIONSISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Nishii, TakaakiDIRECTOR ELECTIONSISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Homma, YoDIRECTOR ELECTIONSISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Watanabe, AkihiroDIRECTOR ELECTIONSISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Kinoshita, ReikoDIRECTOR ELECTIONSISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Stuart MackeyDIRECTOR ELECTIONSISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Corporate Auditor Murata, TakashiCORPORATE GOVERNANCEISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Corporate Auditor Tago, SayuriCORPORATE GOVERNANCEISSUER608000FOR60800FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Approve Details of the Performance-based Stock Compensation to be received by DirectorsCOMPENSATIONISSUER608000FOR60800FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Rainer M. BlairDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Feroz DewanDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Linda FillerDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Charles W. LamannaDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Teri L. ListDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Mitchell P. RalesDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Steven M. RalesDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. A. Shane SandersDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Alan G. SpoonDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Raymond C. Stevens, Ph.DDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Elias A. Zerhouni, MDDIRECTOR ELECTIONSISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To approve on an advisory basis the Company's named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER630580FOR63058FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To approve the Company's Amended and Restated Omnibus Incentive Plan.COMPENSATIONISSUER630580FOR63058FOR19 DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2026DIRECTOR: Jennifer CookDIRECTOR ELECTIONSISSUER222180FOR22218FOR19 DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2026DIRECTOR: David Schenkein, M.D.DIRECTOR ELECTIONSISSUER222180FOR22218FOR19 DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2026DIRECTOR: Ryan Watts, Ph.D.DIRECTOR ELECTIONSISSUER222180FOR22218FOR19 DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2026Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER222180FOR22218FOR19 DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2026Advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER222180FOR22218FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Steven AltmanDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Dr. Euan AshleyDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Nicholas AugustinosDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Richard CollinsDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Rimma DriscollDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Mark FolettaDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Renée GaláDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Bridgette HellerDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Jacob LeachDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Kyle MaladyDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Rick OsterlohDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Kevin SayerDIRECTOR ELECTIONSISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To ratify the selection by the Audit Committee of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER579100FOR57910FOR19 DEXCOM, INC.252131107US252131107405/27/2026To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER579100FOR57910FOR19 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To elect Class II directors, to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Sujay KangoDIRECTOR ELECTIONSISSUER164600FOR16460FOR19 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To elect Class II directors, to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorgeDIRECTOR ELECTIONSISSUER164600FOR16460FOR19 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To elect Class II directors, to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Jonathan Violin, Ph.D.DIRECTOR ELECTIONSISSUER164600FOR16460FOR19 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER164600FOR16460FOR19 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To ratify the appointment of Deloitte & Touche, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER164600FOR16460FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. David LubnerDIRECTOR ELECTIONSISSUER239080FOR23908FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. Brian PosnerDIRECTOR ELECTIONSISSUER239080FOR23908FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. Jason RhodesDIRECTOR ELECTIONSISSUER239080WITHHOLD23908AGAINST19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER239080FOR23908FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares.CAPITAL STRUCTUREISSUER239080FOR23908FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To approve an amendment to our Restated Certificate of Incorporation to provide for officer exculpation.DIRECTOR ELECTIONSISSUER239080FOR23908FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER239080FOR23908FOR19 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026DIRECTOR: Laura BregeDIRECTOR ELECTIONSISSUER222790FOR22279FOR19 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026DIRECTOR: Badreddin Edris, Ph.D.DIRECTOR ELECTIONSISSUER222790ABSTAIN22279AGAINST19 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026DIRECTOR: Jonathan Root, M.D.DIRECTOR ELECTIONSISSUER222790ABSTAIN22279AGAINST19 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026Ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER222790FOR22279FOR19 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER222790FOR22279FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Leslie C. DavisDIRECTOR ELECTIONSISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors David T. Feinberg, MDDIRECTOR ELECTIONSISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Kieran T. GallahueDIRECTOR ELECTIONSISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Leslie S. HeiszDIRECTOR ELECTIONSISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Paul A. LaVioletteDIRECTOR ELECTIONSISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Steven R. LorangerDIRECTOR ELECTIONSISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Ramona SequeiraDIRECTOR ELECTIONSISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Nicholas J. ValerianiDIRECTOR ELECTIONSISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Bernard ZovighianDIRECTOR ELECTIONSISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Advisory Vote to Approve Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Ratification of Appointment of Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER1499050FOR149905FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Approval of the Amended and Restated Long-Term Stock Incentive Compensation ProgramCOMPENSATIONISSUER1499050FOR149905FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Election of two Class I director nominees and three Class II director nominees: Kapila AnandDIRECTOR ELECTIONSISSUER410730FOR41073FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Election of two Class I director nominees and three Class II director nominees: Paul HerendeenDIRECTOR ELECTIONSISSUER410730FOR41073FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Election of two Class I director nominees and three Class II director nominees: Michael HarringtonDIRECTOR ELECTIONSISSUER410730FOR41073FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Election of two Class I director nominees and three Class II director nominees: Lawrence KurziusDIRECTOR ELECTIONSISSUER410730FOR41073FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Election of two Class I director nominees and three Class II director nominees: Kirk McDonaldDIRECTOR ELECTIONSISSUER410730FOR41073FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER410730FOR41073FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Advisory vote on the compensation of the company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER410730FOR41073FOR19 ELEVANCE HEALTH, INC.036752103US036752103805/13/2026Election of Directors: Gail K. BoudreauxDIRECTOR ELECTIONSISSUER77130FOR7713FOR19 ELEVANCE HEALTH, INC.036752103US036752103805/13/2026Election of Directors: Robert L. Dixon, Jr.DIRECTOR ELECTIONSISSUER77130FOR7713FOR19 ELEVANCE HEALTH, INC.036752103US036752103805/13/2026Election of Directors: Deanna D. StrableDIRECTOR ELECTIONSISSUER77130FOR7713FOR19 ELEVANCE HEALTH, INC.036752103US036752103805/13/2026Advisory Vote to Approve the Compensation of Our Named Executive Officers ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER77130FOR7713FOR19 ELEVANCE HEALTH, INC.036752103US036752103805/13/2026Ratification of Ernst & Young LLP as Auditors for 2026.AUDIT-RELATEDISSUER77130FOR7713FOR19 ELEVANCE HEALTH, INC.036752103US036752103805/13/2026Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups.OTHER SOCIAL ISSUESSECURITY HOLDER77130AGAINST7713FOR19 ELI LILLY AND COMPANY532457108US532457108305/04/2026Election of the following directors, each to serve a three-year term. Carolyn BertozziDIRECTOR ELECTIONSISSUER454360FOR45436FOR19 ELI LILLY AND COMPANY532457108US532457108305/04/2026Election of the following directors, each to serve a three-year term. William Kaelin, Jr.DIRECTOR ELECTIONSISSUER454360FOR45436FOR19 ELI LILLY AND COMPANY532457108US532457108305/04/2026Election of the following directors, each to serve a three-year term. Jon MoellerDIRECTOR ELECTIONSISSUER454360FOR45436FOR19 ELI LILLY AND COMPANY532457108US532457108305/04/2026Election of the following directors, each to serve a three-year term. David RicksDIRECTOR ELECTIONSISSUER454360FOR45436FOR19 ELI LILLY AND COMPANY532457108US532457108305/04/2026Approval, on an advisory basis, of the compensation paid to the company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER454360FOR45436FOR19 ELI LILLY AND COMPANY532457108US532457108305/04/2026Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2026.AUDIT-RELATEDISSUER454360FOR45436FOR19 ELI LILLY AND COMPANY532457108US532457108305/04/2026Approval of amendments to the company's articles of incorporation to eliminate the classified board structure.SHAREHOLDER RIGHTS AND DEFENSESISSUER454360FOR45436FOR19 ELI LILLY AND COMPANY532457108US532457108305/04/2026Approval of amendments to the company's articles of incorporation to eliminate supermajority voting provisions.SHAREHOLDER RIGHTS AND DEFENSESISSUER454360FOR45436FOR19 ELI LILLY AND COMPANY532457108US532457108305/04/2026Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair.CORPORATE GOVERNANCESECURITY HOLDER454360AGAINST45436FOR19 ELI LILLY AND COMPANY532457108US532457108305/04/2026Shareholder proposal to prepare an annual lobbying report.OTHER SOCIAL ISSUESSECURITY HOLDER454360AGAINST45436FOR19 ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To elect two Class I directors to serve until the 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified. Bruce L.A. Carter, Ph.D.DIRECTOR ELECTIONSISSUER425120FOR42512FOR19 ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To elect two Class I directors to serve until the 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified. Jay R. Luly, Ph.D.DIRECTOR ELECTIONSISSUER425120FOR42512FOR19 ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To approve an amendment to our 2019 Equity Incentive Plan.COMPENSATIONISSUER425120FOR42512FOR19 ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER425120FOR42512FOR19 ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To ratify the appointment of PricewaterhouseCoopers LLP as Enanta's independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER425120FOR42512FOR19 ERASCA, INC.29479A108US29479A108806/26/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified Alexander W. CasdinDIRECTOR ELECTIONSISSUER622820FOR62282FOR19 ERASCA, INC.29479A108US29479A108806/26/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified Julie Hambleton, M.D.DIRECTOR ELECTIONSISSUER622820FOR62282FOR19 ERASCA, INC.29479A108US29479A108806/26/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified Michael D. Varney, Ph.D.DIRECTOR ELECTIONSISSUER622820FOR62282FOR19 ERASCA, INC.29479A108US29479A108806/26/2026To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026AUDIT-RELATEDISSUER622820FOR62282FOR19 EXACT SCIENCES CORPORATION30063P105US30063P105702/20/2026Proposal to adopt the Agreement and Plan of Merger, dated as of November 19, 2025, as it may be amended from time to time (the "Merger Agreement"), by and among Exact Sciences Corporation, Abbott Laboratories and Badger Merger Sub I, Inc. (the "Merger Agreement Proposal").EXTRAORDINARY TRANSACTIONSISSUER478100FOR47810FOR19 EXACT SCIENCES CORPORATION30063P105US30063P105702/20/2026Proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to Exact Sciences Corporation's named executive officers that is based on or otherwise related to the Merger Agreement and the transactions contemplated by the Merger Agreement (the "Compensation Proposal").SECTION 14A SAY-ON-PAY VOTESISSUER478100FOR47810FOR19 EXACT SCIENCES CORPORATION30063P105US30063P105702/20/2026Proposal to approve any adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the Special Meeting to approve the Merger Agreement Proposal (the "Adjournment Proposal").CORPORATE GOVERNANCEISSUER478100FOR47810FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Mary C. Beckerle, Ph.D.DIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. S. Gail Eckhardt, M.D.DIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Maria C. Freire, Ph.D.DIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Tomas J. HeymanDIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. David E. JohnsonDIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Michael M. Morrissey, Ph.D.DIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Robert L. Oliver, Jr.DIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Stelios Papadopoulos, Ph.D.DIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. George Poste, DVM, Ph.D., FRSDIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Julie Anne SmithDIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Jack L. WyszomierskiDIRECTOR ELECTIONSISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the fiscal year ending January 1, 2027.AUDIT-RELATEDISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To amend and restate the Exelixis, Inc. 2017 Equity Incentive Plan to, among other things, increase the number of shares authorized for issuance by 2,000,000 shares.COMPENSATIONISSUER198630FOR19863FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER198630FOR19863FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Göran Ando, M.D.DIRECTOR ELECTIONSISSUER163200FOR16320FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Jay S. Duker, M.D.DIRECTOR ELECTIONSISSUER163200FOR16320FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: John B. Landis, Ph.D.DIRECTOR ELECTIONSISSUER163200FOR16320FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Wendy DiCiccoDIRECTOR ELECTIONSISSUER163200FOR16320FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Karen ZaderejDIRECTOR ELECTIONSISSUER163200FOR16320FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Stuart DutyDIRECTOR ELECTIONSISSUER163200FOR16320FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Fred HassanDIRECTOR ELECTIONSISSUER163200FOR16320FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Reginald Sanders, M.D.DIRECTOR ELECTIONSISSUER163200FOR16320FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026To approve Amendment No. 3 to the EyePoint, Inc. 2023 Long-Term Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 4,900,000 shares.COMPENSATIONISSUER163200FOR16320FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER163200FOR16320FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER163200FOR16320FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Non-Financial ReportOTHER SOCIAL ISSUESISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Remuneration Report (Non-Binding)SECTION 14A SAY-ON-PAY VOTESISSUER165990AGAINST16599AGAINST19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Allocation of Income and Dividends of CHF 0.35 per Share from Capital Contribution ReservesCAPITAL STRUCTUREISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Discharge of Board and Senior ManagementDIRECTOR ELECTIONSISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Thomas Ebeling as Director and Board ChairDIRECTOR ELECTIONSISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Daniel Browne as DirectorDIRECTOR ELECTIONSISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Maria Hilado as DirectorDIRECTOR ELECTIONSISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Karen Ling as DirectorDIRECTOR ELECTIONSISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Roberto Marques as DirectorDIRECTOR ELECTIONSISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Sherilyn McCoy as DirectorDIRECTOR ELECTIONSISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Flemming Ornskov as DirectorDIRECTOR ELECTIONSISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Elect Harry Kirsch as DirectorDIRECTOR ELECTIONSISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Elect Samuel du Retail as DirectorDIRECTOR ELECTIONSISSUER165990AGAINST16599NONE19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Elect Delphine Viguier-Hovasse as DirectorDIRECTOR ELECTIONSISSUER165990AGAINST16599NONE19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reappoint Karen Ling as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reappoint Thomas Ebeling as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reappoint Roberto Marques as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Remuneration of Directors in the Amount of CHF 3.2 MillionCOMPENSATIONISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Remuneration of Executive Committee in the Amount of CHF 31.2 MillionCOMPENSATIONISSUER165990AGAINST16599AGAINST19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Designate Altenburger Ltd as Independent ProxyCORPORATE GOVERNANCEISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Ratify KPMG AG as AuditorsAUDIT-RELATEDISSUER165990FOR16599FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Transact Other Business (Voting)CORPORATE GOVERNANCEISSUER165990ABSTAIN16599AGAINST19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Share Re-registration ConsentCORPORATE GOVERNANCEISSUER165990FOR16599FOR19 GE HEALTHCARE TECHNOLOGIES INC.36266G107US36266G107605/07/2026Election of Directors Peter J. ArduiniDIRECTOR ELECTIONSISSUER209170FOR20917FOR19 GE HEALTHCARE TECHNOLOGIES INC.36266G107US36266G107605/07/2026Election of Directors H. Lawrence Culp, Jr.DIRECTOR ELECTIONSISSUER209170FOR20917FOR19 GE HEALTHCARE TECHNOLOGIES INC.36266G107US36266G107605/07/2026Election of Directors Rodney F. HochmanDIRECTOR ELECTIONSISSUER209170FOR20917FOR19 GE HEALTHCARE TECHNOLOGIES INC.36266G107US36266G107605/07/2026Election of Directors Catherine LesjakDIRECTOR ELECTIONSISSUER209170AGAINST20917AGAINST19 GE HEALTHCARE TECHNOLOGIES INC.36266G107US36266G107605/07/2026Election of Directors Kevin A. LoboDIRECTOR ELECTIONSISSUER209170FOR20917FOR19 GE HEALTHCARE TECHNOLOGIES INC.36266G107US36266G107605/07/2026Election of Directors Anne T. MaddenDIRECTOR ELECTIONSISSUER209170FOR20917FOR19 GE HEALTHCARE TECHNOLOGIES INC.36266G107US36266G107605/07/2026Election of Directors William J. StrombergDIRECTOR ELECTIONSISSUER209170FOR20917FOR19 GE HEALTHCARE TECHNOLOGIES INC.36266G107US36266G107605/07/2026Election of Directors Phoebe L. YangDIRECTOR ELECTIONSISSUER209170FOR20917FOR19 GE HEALTHCARE TECHNOLOGIES INC.36266G107US36266G107605/07/2026Approval of our named executive officers' compensation in an advisory vote.SECTION 14A SAY-ON-PAY VOTESISSUER209170FOR20917FOR19 GE HEALTHCARE TECHNOLOGIES INC.36266G107US36266G107605/07/2026Ratification of the appointment of Deloitte & Touche LLP as our independent auditor for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER209170FOR20917FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Jacqueline K. Barton, Ph.D.DIRECTOR ELECTIONSISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Jeffrey A. Bluestone, Ph.D.DIRECTOR ELECTIONSISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Sandra J. Horning, M.D.DIRECTOR ELECTIONSISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Kelly A. KramerDIRECTOR ELECTIONSISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Ted W. Love, M.D.DIRECTOR ELECTIONSISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Harish ManwaniDIRECTOR ELECTIONSISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Daniel P. O'DayDIRECTOR ELECTIONSISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Javier J. RodriguezDIRECTOR ELECTIONSISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Anthony WeltersDIRECTOR ELECTIONSISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.COMPENSATIONISSUER1504870FOR150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.CORPORATE GOVERNANCESECURITY HOLDER1504870AGAINST150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.OTHER SOCIAL ISSUESSECURITY HOLDER1504870AGAINST150487FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.CORPORATE GOVERNANCEDIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER1504870AGAINST150487FOR19 GLAUKOS CORPORATION377322102US377322102905/28/2026DIRECTOR: Denice M. TorresDIRECTOR ELECTIONSISSUER76250FOR7625FOR19 GLAUKOS CORPORATION377322102US377322102905/28/2026DIRECTOR: Aimee S. WeisnerDIRECTOR ELECTIONSISSUER76250FOR7625FOR19 GLAUKOS CORPORATION377322102US377322102905/28/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER76250FOR7625FOR19 GLAUKOS CORPORATION377322102US377322102905/28/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER76250FOR7625FOR19 GOSSAMER BIO, INC.38341P102US38341P102106/04/2026Election of Class II Directors Russell CoxDIRECTOR ELECTIONSISSUER319550FOR31955FOR19 GOSSAMER BIO, INC.38341P102US38341P102106/04/2026Election of Class II Directors Faheem HasnainDIRECTOR ELECTIONSISSUER319550FOR31955FOR19 GOSSAMER BIO, INC.38341P102US38341P102106/04/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accountants for the year ending December 31, 2026.AUDIT-RELATEDISSUER319550FOR31955FOR19 GOSSAMER BIO, INC.38341P102US38341P102106/04/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER319550FOR31955FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Election of Directors Thomas F. Frist IIIDIRECTOR ELECTIONSISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Election of Directors Samuel N. HazenDIRECTOR ELECTIONSISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Election of Directors John W. Chidsey, IIIDIRECTOR ELECTIONSISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Election of Directors Nancy-Ann DeParleDIRECTOR ELECTIONSISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Election of Directors William R. FristDIRECTOR ELECTIONSISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Election of Directors Hugh F. JohnstonDIRECTOR ELECTIONSISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Election of Directors Michael W. MichelsonDIRECTOR ELECTIONSISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Election of Directors Wayne J. Riley, M.D.DIRECTOR ELECTIONSISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Election of Directors Andrea B. SmithDIRECTOR ELECTIONSISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER109370FOR10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences.HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCESECURITY HOLDER109370AGAINST10937FOR19 HCA HEALTHCARE, INC.40412C101US40412C101804/23/2026Stockholder proposal, if properly presented at the meeting, regarding shareholders' right to act by written consent.SHAREHOLDER RIGHTS AND DEFENSESSECURITY HOLDER109370AGAINST10937FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025To consider and vote upon a proposal to approve, by ordinary resolution, and adopt the Business Combination Agreement, dated as of February 28, 2025 (as amended by Amendment No. 1 to the Business Combination Agreement, dated as of June 17, 2025, and as it may be further amended, restated, supplemented, or otherwise modified from time to time, the "Business Combination Agreement"), by and among Helix, Helix II Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Helix ("Merger Sub"), and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), a Delaware corporation ("BBOT"), and the transactions contemplated by the Business Combination Agreement, pursuant to which the following will occur: (1) the domestication of Helix as a Delaware corporation, in which Helix will de-register from the Register of Companies in the Cayman Islands and transfer by way of continuation out of the Cayman Islands and into the State of Delaware so as to migrate to and domesticate as a Delaware corporation in accordance with the Helix Articles, Section 388 of the Delaware General Corporation Law (the "DGCL") and Part XII of the Companies Act (As Revised) of the Cayman Islands (the "Cayman Companies Act") (the "Domestication"); (2) the merger of Merger Sub with and into BBOT with BBOT surviving the merger as a wholly-owned subsidiary of Helix (the "Merger"), in accordance with the Business Combination Agreement and DGCL; and (3) the other transactions contemplated by the Business Combination Agreement and documents related thereto (such transactions, together with the Domestication and the Merger, the "Business Combination"), all as described in more detail in the accompanying proxy statement/prospectus. In connection with the consummation of the Business Combination (the "Closing" and the date of the Closing, the "Closing Date"), Helix will be renamed BridgeBio Oncology Therapeutics, Inc. ("PubCo"). References herein to PubCo denote Helix following the Business Combination. We refer to this proposal as the "Business Combination Proposal." A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus as Annex A.EXTRAORDINARY TRANSACTIONSISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The Domestication Proposal - to consider and vote upon a proposal to approve, by special resolution, the deregistration of Helix from the Registrar of Companies in the Cayman Islands (the "Cayman Registrar") and transfer by way of continuation out of the Cayman Islands and into the State of Delaware so as to migrate to and domesticate as a Delaware corporation in accordance with the Helix Articles, Section 388 of the DGCL, and Part XII of the Cayman Companies Act.EXTRAORDINARY TRANSACTIONSISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The Stock Issuance Proposal - to consider and vote upon a proposal to approve, by ordinary resolution, including for purposes of complying with the applicable provisions of Nasdaq Listing Rules 5635(a), (b) and (d), the issuance or potential issuance of (i) shares of common stock, par value $0.0001 per share, of PubCo (the "PubCo Common Stock") to the shareholders of Helix in the Domestication and stockholders of BBOT in the Merger pursuant to the Business Combination Agreement, (ii) shares of PubCo Common Stock to the PIPE Investors in the PIPE Investment pursuant to the Subscription Agreements, and (iii) any other issuances of PubCo Common Stock and securities convertible into or exercisable for PubCo Common Stock pursuant to subscription, purchase or similar agreements Helix has entered, or may enter, into prior to Closing.CAPITAL STRUCTUREISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The Organizational Documents Proposal - to consider and vote upon a proposal to approve, by special resolution, the proposed new certificate of incorporation of PubCo (the "PubCo Charter") and the proposed new bylaws of PubCo (the "PubCo Bylaws" and, together with the PubCo Charter, the "PubCo Organizational Documents") in connection with the Business Combination. The form of each of the PubCo Charter and the PubCo Bylaws is attached to the proxy statement/prospectus as Annex I and Annex J, respectively.CORPORATE GOVERNANCEISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Authorized Shares - A proposal to amend the Helix Articles to authorize the change in the authorized capital stock of Helix from (i) 500,000,000 Helix Class A Shares, 50,000,000 Helix Class B Shares and 5,000,000 preference shares, par value $0.0001 per share, to (ii) 500,000,000 shares of PubCo Common Stock and 10,000,000 shares of undesignated PubCo preferred stock.CAPITAL STRUCTUREISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Exclusive Forum Provision - A proposal to amend the Helix Articles to authorize adopting Delaware as the exclusive forum for certain stockholder litigation.SHAREHOLDER RIGHTS AND DEFENSESISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Adoption of Supermajority Vote Requirement to Amend the Proposed Organizational Documents - A proposal to amend the Helix Articles to approve provisions requiring the affirmative vote of at least (i) two-thirds of the outstanding shares of capital stock entitled to vote to adopt, amend or repeal the PubCo Bylaws and (ii) a majority of PubCo's then outstanding common stock (except where a lower threshold is provided by the DGCL) for amendments to the PubCo Charter.SHAREHOLDER RIGHTS AND DEFENSESISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Removal of Directors - A proposal to amend the Helix Articles to approve provisions permitting the removal of a director only for cause and only by the affirmative vote of not less than two-thirds of the outstanding shares entitled to vote at an election of directors, voting together as a single class.SHAREHOLDER RIGHTS AND DEFENSESISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Action by Written Consent of Stockholders - A proposal to amend the Helix Articles to approve provisions requiring stockholders to take action at an annual or special meeting and prohibiting stockholder action by written consent in lieu of a meeting.SHAREHOLDER RIGHTS AND DEFENSESISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Other Changes in Connection with Adoption of the proposed PubCo Organizational Documents - A proposal to amend the Helix Articles to authorize (1) changing the corporate name from "Helix Acquisition Corp. II" to "BridgeBio Oncology Therapeutics, Inc.", (2) making PubCo's corporate existence perpetual, and (3) removing certain provisions related to Helix's status as a blank check company that will no longer be applicable upon consummation of the Business Combination.CORPORATE GOVERNANCEISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The Incentive Plan Proposal - to consider and vote upon a proposal to approve, by ordinary resolution, the BridgeBio Oncology Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "PubCo Incentive Plan").COMPENSATIONISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The ESPP Proposal - to consider and vote upon a proposal to approve, by ordinary resolution, the BridgeBio Oncology Therapeutics, Inc. 2025 Employee Stock Purchase Plan (the "ESPP").COMPENSATIONISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Eli Wallace, Ph.DDIRECTOR ELECTIONSISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Neil Kumar, Ph.DDIRECTOR ELECTIONSISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Frank McCormick, Ph.D.DIRECTOR ELECTIONSISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Praveen Tipirneni, M.D.DIRECTOR ELECTIONSISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Michelle DoigDIRECTOR ELECTIONSISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Bihua ChenDIRECTOR ELECTIONSISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Raymond Kelleher, M.D.DIRECTOR ELECTIONSISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Jake Bauer, M.B.A.DIRECTOR ELECTIONSISSUER615300FOR61530FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The Adjournment Proposal - to consider and vote upon a proposal to approve, by ordinary resolution, the adjournment of the EGM to a later date or dates, if necessary or desirable.CORPORATE GOVERNANCEISSUER615300FOR61530FOR19 HOLOGIC, INC.436440101US436440101202/05/2026A proposal to adopt the Agreement and Plan of Merger, dated as of October 21, 2025 (as it may be amended or supplemented from time to time, the "merger agreement"), by and among Hologic, Inc. (the "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, and on the terms and subject to the conditions thereof, Merger Sub will be merged with and into the Company (the "merger"), with the Company surviving the merger as a wholly owned subsidiary of Parent.EXTRAORDINARY TRANSACTIONSISSUER121930FOR12193FOR19 HOLOGIC, INC.436440101US436440101202/05/2026A proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the transactions contemplated by the merger agreement, including consummation of the merger.SECTION 14A SAY-ON-PAY VOTESISSUER121930FOR12193FOR19 HOLOGIC, INC.436440101US436440101202/05/2026A proposal to approve any adjournment of the special meeting for the purpose of soliciting additional proxies if there are insufficient votes at the special meeting to adopt the merger agreement.CORPORATE GOVERNANCEISSUER121930FOR12193FOR19 HUMANA INC.444859102US444859102804/16/2026Election of Directors Raquel C. Bono, M.DDIRECTOR ELECTIONSISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026Election of Directors Frank A. D'AmelioDIRECTOR ELECTIONSISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026Election of Directors David T. Feinberg, M.D.DIRECTOR ELECTIONSISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026Election of Directors Wayne A. I. Frederick, M.D.DIRECTOR ELECTIONSISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026Election of Directors Kurt J. HilzingerDIRECTOR ELECTIONSISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026Election of Directors Karen W. KatzDIRECTOR ELECTIONSISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026Election of Directors Marcy S. KlevornDIRECTOR ELECTIONSISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026Election of Directors Jorge S. MesquitaDIRECTOR ELECTIONSISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026Election of Directors James A. RechtinDIRECTOR ELECTIONSISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026Election of Directors Gordon SmithDIRECTOR ELECTIONSISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026The ratification of the appointment of Pricewater-houseCoopers LLP as the Company's independent registered public accounting firm.AUDIT-RELATEDISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026The approval of the Humana Inc. 2026 Stock Incentive Plan.COMPENSATIONISSUER67650FOR6765FOR19 HUMANA INC.444859102US444859102804/16/2026The stockholder proposal requesting shareholder approval requirement for excessive golden parachutes, if properly presented at the meeting.COMPENSATIONSECURITY HOLDER67650AGAINST6765FOR19 IDEXX LABORATORIES, INC.45168D104US45168D104605/12/2026Election of Directors (Proposal One). Daniel M. JuniusDIRECTOR ELECTIONSISSUER67120FOR6712FOR19 IDEXX LABORATORIES, INC.45168D104US45168D104605/12/2026Election of Directors (Proposal One). Lawrence D. KingsleyDIRECTOR ELECTIONSISSUER67120FOR6712FOR19 IDEXX LABORATORIES, INC.45168D104US45168D104605/12/2026Election of Directors (Proposal One). Sophie V. Vandebroek, PhDDIRECTOR ELECTIONSISSUER67120FOR6712FOR19 IDEXX LABORATORIES, INC.45168D104US45168D104605/12/2026Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year (Proposal Two).AUDIT-RELATEDISSUER67120FOR6712FOR19 IDEXX LABORATORIES, INC.45168D104US45168D104605/12/2026Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation (Proposal Three).SECTION 14A SAY-ON-PAY VOTESISSUER67120FOR6712FOR19 IDEXX LABORATORIES, INC.45168D104US45168D104605/12/2026Amend Certificate of Incorporation to Declassify the Board (Proposal Four).SHAREHOLDER RIGHTS AND DEFENSESISSUER67120FOR6712FOR19 IDEXX LABORATORIES, INC.45168D104US45168D104605/12/2026Amend Certificate of Incorporation to Provide Shareholders Owning 25% of the Shares of our Capital Stock the Right to Have IDEXX Call a Special Meeting (Proposal Five).SHAREHOLDER RIGHTS AND DEFENSESISSUER67120FOR6712FOR19 IDEXX LABORATORIES, INC.45168D104US45168D104605/12/2026Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six).SHAREHOLDER RIGHTS AND DEFENSESCORPORATE GOVERNANCESECURITY HOLDER67120AGAINST6712FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Caroline D. DorsaDIRECTOR ELECTIONSISSUER132930FOR13293FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Scott Gottlieb, M.D.DIRECTOR ELECTIONSISSUER132930FOR13293FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors David P. KingDIRECTOR ELECTIONSISSUER132930FOR13293FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Keith A. MeisterDIRECTOR ELECTIONSISSUER132930FOR13293FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Anna RichoDIRECTOR ELECTIONSISSUER132930FOR13293FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Philip W. SchillerDIRECTOR ELECTIONSISSUER132930FOR13293FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Susan E. SiegelDIRECTOR ELECTIONSISSUER132930FOR13293FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Jacob Thaysen, Ph.D.DIRECTOR ELECTIONSISSUER132930FOR13293FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Scott B. UllemDIRECTOR ELECTIONSISSUER132930FOR13293FOR19 ILLUMINA, INC.452327109US452327109005/21/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 3, 2027.AUDIT-RELATEDISSUER132930FOR13293FOR19 ILLUMINA, INC.452327109US452327109005/21/2026To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER132930FOR13293FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To re-appoint Siddharth Kaul as a director who retires in accordance with the articles of association. Siddharth KaulDIRECTOR ELECTIONSISSUER165650FOR16565FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To re-appoint William Pao, M.D., Ph.D. as a director who retires in accordance with the articles of association. William Pao, M.D., Ph.D.DIRECTOR ELECTIONSISSUER165650FOR16565FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To re-appoint Kristine Peterson as a director who retires in accordance with the articles of association. Kristine PetersonDIRECTOR ELECTIONSISSUER165650FOR16565FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER165650FOR16565FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To ratify the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending 31 December 2026.AUDIT-RELATEDISSUER165650FOR16565FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To re-appoint Deloitte LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.AUDIT-RELATEDISSUER165650FOR16565FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To authorize the audit committee to determine the U.K. statutory auditors' remuneration for the year ending 31 December 2026.AUDIT-RELATEDCOMPENSATIONISSUER165650FOR16565FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To receive and adopt the U.K. statutory annual accounts and reports for the year ended 31 December 2025.CORPORATE GOVERNANCEISSUER165650FOR16565FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To approve our directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the attached proxy statement and on pages 26 to 56 of the 2025 U.K. Annual Report (excluding the directors' remuneration policy set out on 26 to 56 2025 U.K. Annual Report (excluding the directors' remuneration policy set out on A7 to A18 of Annex A).SECTION 14A SAY-ON-PAY VOTESISSUER165650FOR16565FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To authorize the Company and all of its subsidiaries to make political donations and incur political expenditure.OTHER SOCIAL ISSUESISSUER165650FOR16565FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal. James BoylanDIRECTOR ELECTIONSISSUER253400FOR25340FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal. Sandra M. Swain, M.D.DIRECTOR ELECTIONSISSUER253400FOR25340FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal. Philip WagenheimDIRECTOR ELECTIONSISSUER253400FOR25340FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To ratify the appointment of Ernst & Young LLP our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER253400FOR25340FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER253400FOR25340FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2534001 YEAR25340FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Julian C. BakerDIRECTOR ELECTIONSISSUER345680FOR34568FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jean-Jacques BienaiméDIRECTOR ELECTIONSISSUER345680FOR34568FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Otis W. BrawleyDIRECTOR ELECTIONSISSUER345680FOR34568FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Paul J. ClancyDIRECTOR ELECTIONSISSUER345680FOR34568FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jacqualyn A. FouseDIRECTOR ELECTIONSISSUER345680FOR34568FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Edmund P. HarriganDIRECTOR ELECTIONSISSUER345680FOR34568FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Katherine A. HighDIRECTOR ELECTIONSISSUER345680FOR34568FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: William J. MeuryDIRECTOR ELECTIONSISSUER345680FOR34568FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER345680FOR34568FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER345680FOR34568FOR19 INSMED INCORPORATED457669307US457669307505/13/2026DIRECTOR: E. McKee AndersonDIRECTOR ELECTIONSISSUER264400FOR26440FOR19 INSMED INCORPORATED457669307US457669307505/13/2026DIRECTOR: C. Desjardins, Ph.D.DIRECTOR ELECTIONSISSUER264400FOR26440FOR19 INSMED INCORPORATED457669307US457669307505/13/2026An advisory vote on the 2025 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER264400FOR26440FOR19 INSMED INCORPORATED457669307US457669307505/13/2026Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER264400FOR26440FOR19 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/09/2026Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. Muna Bhanji, R.Ph.DIRECTOR ELECTIONSISSUER457050FOR45705FOR19 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/09/2026Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. Brian GoffDIRECTOR ELECTIONSISSUER457050FOR45705FOR19 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/09/2026Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. Jesse Goodman, M.D., M.P.H.DIRECTOR ELECTIONSISSUER457050FOR45705FOR19 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/09/2026Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER457050FOR45705FOR19 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/09/2026Approval, on a non-binding advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER457050FOR45705FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Craig H. Barratt, Ph.D.DIRECTOR ELECTIONSISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Joseph C. BeeryDIRECTOR ELECTIONSISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Lewis ChewDIRECTOR ELECTIONSISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Gary S. Guthart, Ph.D.DIRECTOR ELECTIONSISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Sreelakshmi KolliDIRECTOR ELECTIONSISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Amy L. Ladd, M.D.DIRECTOR ELECTIONSISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Keith R. Leonard, Jr.DIRECTOR ELECTIONSISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Jami Dover NachtsheimDIRECTOR ELECTIONSISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Monica P. Reed, M.D.DIRECTOR ELECTIONSISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors David J. RosaDIRECTOR ELECTIONSISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026To approve, by advisory vote, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026The ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER275050FOR27505FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026To approve the amendment and restatement of the Company's Amended and Restated 2010 Incentive Award Plan.COMPENSATIONISSUER275050FOR27505FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026Election of Directors Spencer R. BerthelsenDIRECTOR ELECTIONSISSUER149830FOR14983FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026Election of Directors Joan E. HermanDIRECTOR ELECTIONSISSUER149830FOR14983FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026To make an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER149830FOR14983FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares.COMPENSATIONISSUER149830FOR14983FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026To approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for purchase under such plan by 750,000 shares and remove the termination date of the plan.COMPENSATIONISSUER149830FOR14983FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year.AUDIT-RELATEDISSUER149830FOR14983FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). Ari BousbibDIRECTOR ELECTIONSISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). Carol J. BurtDIRECTOR ELECTIONSISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). John G. DanhaklDIRECTOR ELECTIONSISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). James A. FasanoDIRECTOR ELECTIONSISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). Colleen A. GogginsDIRECTOR ELECTIONSISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). William G. Kaelin Jr., M.D.DIRECTOR ELECTIONSISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). John M. Leonard, M.D.DIRECTOR ELECTIONSISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). Leslie Wims MorrisDIRECTOR ELECTIONSISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). Sheila A. StampsDIRECTOR ELECTIONSISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026Approve an advisory (non-binding) resolution to approve IQVIA's executive compensation (say-on-pay).SECTION 14A SAY-ON-PAY VOTESISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026Ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA's independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026Approve the adoption of the IQVIA Holdings Inc. 2026 Incentive and Stock Award Plan.COMPENSATIONISSUER125020FOR12502FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles.CORPORATE GOVERNANCESECURITY HOLDER125020AGAINST12502FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Mary C. BeckerleDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Jennifer A. DoudnaDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Joaquin DuatoDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Marillyn A. HewsonDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Paula A. JohnsonDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Hubert JolyDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Mark B. McClellanDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors John G. MorikisDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Daniel E. PintoDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Mark A. WeinbergerDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Nadja Y. WestDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Eugene A. WoodsDIRECTOR ELECTIONSISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Advisory Vote to Approve Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Ratification of Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER2313410FOR231341FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Independent Board ChairCORPORATE GOVERNANCESECURITY HOLDER2313410AGAINST231341FOR19 KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Elect three Class II directors nominated by our board and named in this proxy statement. Charles A. BancroftDIRECTOR ELECTIONSISSUER113890WITHHOLD11389AGAINST19 KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Elect three Class II directors nominated by our board and named in this proxy statement. Bassil I. Dahiyat, Ph.D.DIRECTOR ELECTIONSISSUER113890FOR11389FOR19 KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Elect three Class II directors nominated by our board and named in this proxy statement. Taiyin Yang, Ph.D.DIRECTOR ELECTIONSISSUER113890FOR11389FOR19 KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER113890FOR11389FOR19 KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER113890FOR11389FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026DIRECTOR: Bruce Booth, D.Phil.DIRECTOR ELECTIONSISSUER47120FOR4712FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026DIRECTOR: Nello Mainolfi, Ph.D.DIRECTOR ELECTIONSISSUER47120FOR4712FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026DIRECTOR: John Maraganore, Ph.D.DIRECTOR ELECTIONSISSUER47120FOR4712FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026DIRECTOR: Elena Ridloff, CFADIRECTOR ELECTIONSISSUER47120FOR4712FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER47120FOR4712FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026To ratify the appointment of Ernst &Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER47120FOR4712FOR19 LB PHARMACEUTICALS INC.50180M108US50180M108006/03/2026DIRECTOR: Robert A. Lenz MD., PhDDIRECTOR ELECTIONSISSUER3750810800FOR37508FOR19 LB PHARMACEUTICALS INC.50180M108US50180M108006/03/2026DIRECTOR: Rebecca LuseDIRECTOR ELECTIONSISSUER3750810800FOR37508FOR19 LB PHARMACEUTICALS INC.50180M108US50180M108006/03/2026DIRECTOR: Ran NussbaumDIRECTOR ELECTIONSISSUER3750810800FOR37508FOR19 LB PHARMACEUTICALS INC.50180M108US50180M108006/03/2026To ratify the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER3750810800FOR37508FOR19 MAPLIGHT THERAPEUTICS, INC.56565P103US56565P103006/23/2026To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. Martin BablerDIRECTOR ELECTIONSISSUER26791785FOR2679FOR19 MAPLIGHT THERAPEUTICS, INC.56565P103US56565P103006/23/2026To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. Troy CoxDIRECTOR ELECTIONSISSUER26791785FOR2679FOR19 MAPLIGHT THERAPEUTICS, INC.56565P103US56565P103006/23/2026To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. George PavlovDIRECTOR ELECTIONSISSUER26791785FOR2679FOR19 MAPLIGHT THERAPEUTICS, INC.56565P103US56565P103006/23/2026To ratify the appointment by the Audit Committee of our Board of Directors of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER26791785FOR2679FOR19 MAZE THERAPEUTICS INC578784100US578784100706/08/2026DIRECTOR: Jason Coloma, Ph.D.DIRECTOR ELECTIONSISSUER148651100FOR14865FOR19 MAZE THERAPEUTICS INC578784100US578784100706/08/2026DIRECTOR: Neil Kumar, Ph.D.DIRECTOR ELECTIONSISSUER148651100FOR14865FOR19 MAZE THERAPEUTICS INC578784100US578784100706/08/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER148651100FOR14865FOR19 MBX BIOSCIENCES55287L101US55287L101706/04/2026Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholder and until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Patrick J. HeronDIRECTOR ELECTIONSISSUER284570FOR28457FOR19 MBX BIOSCIENCES55287L101US55287L101706/04/2026Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholder and until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Edward T. MathersDIRECTOR ELECTIONSISSUER284570WITHHOLD28457AGAINST19 MBX BIOSCIENCES55287L101US55287L101706/04/2026Ratification of the appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026.AUDIT-RELATEDISSUER284570FOR28457FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Dominic J. CarusoDIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Lynne M. DoughtieDIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: W. Roy DunbarDIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Deborah Dunsire, M.D.DIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Julie L. Gerberding, M.D., M.P.H.DIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: James H. HintonDIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Donald R. KnaussDIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Bradley E. LermanDIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Maria N. MartinezDIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Kevin M. OzanDIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Brian S. TylerDIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Kathleen Wilson-ThompsonDIRECTOR ELECTIONSISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Ratification of Appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2026AUDIT-RELATEDISSUER113030FOR11303FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Advisory Vote to Approve the Company's Executive CompensationSECTION 14A SAY-ON-PAY VOTESISSUER113030FOR11303FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Charles N. MillsDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Joseph P. BarattaDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Jacob D. BestDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Todd M. BluedornDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: James M. BoyleDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Richard A. GalantiDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Patrick J. HealyDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Andrew J. MillsDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Robert R. SchmidtDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Anushka M. SunderDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Thomas W. SweetDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Stephen H. WiseDIRECTOR ELECTIONSISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026Advisory Vote to Approve Our Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER706450FOR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026Advisory Vote on the Frequency of Votes on Our Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER7064501 YEAR70645FOR19 MEDLINE INC.58507V107US58507V107006/11/2026Ratification of the Selection of Ernst & Young LLP as Our Independent Auditor for Fiscal Year 2026.AUDIT-RELATEDISSUER706450FOR70645FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Craig ArnoldDIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Scott C. DonnellyDIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Lidia L. FonsecaDIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); John P. GroetelaarsDIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Randall J. Hogan, IIIDIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); William R. JellisonDIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Joon S. Lee, M.D.DIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Gregory P. LewisDIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Kevin E. LoftonDIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Geoffrey S. MarthaDIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Elizabeth G. Nabel, M.D.DIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Kendall J. PowellDIRECTOR ELECTIONSISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for fiscal year 2026 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor's remuneration;AUDIT-RELATEDCOMPENSATIONISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Approving, on an advisory basis, the Company's executive compensation;SECTION 14A SAY-ON-PAY VOTESISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Renewing the Board of Directors' authority to issue shares under Irish law;CAPITAL STRUCTUREISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Renewing the Board of Directors' authority to opt out of pre-emption rights under Irish law;CAPITAL STRUCTUREISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares;CAPITAL STRUCTUREISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Approving an amendment to Article 177 of the Company's Articles of Association, to facilitate the capitalization of certain of the Company's non-distributable reserves;CAPITAL STRUCTUREISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Approving a Capital Reduction to Create Distributable Reserves under Irish Law; andCAPITAL STRUCTUREISSUER1879460FOR187946FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Approving amendments to the Company's Articles of Association, to update the advance notice provisions.SHAREHOLDER RIGHTS AND DEFENSESISSUER1879460FOR187946FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Douglas M. Baker, Jr.DIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Mary Ellen CoeDIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Pamela J. CraigDIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Robert M. DavisDIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Thomas H. GlocerDIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Surendralal L. KarsanbhaiDIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Risa J. Lavizzo-Mourey, M.D.DIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Stephen L. Mayo, Ph.D.DIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Paul B. Rothman, M.D.DIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Patricia F. RussoDIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Christine E. Seidman, M.D.DIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Inge G. ThulinDIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Kathy J. WardenDIRECTOR ELECTIONSISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Non-binding advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Ratification of the appointment of the Company's independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER2052770FOR205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Shareholder proposal regarding a report on DEI risks in federal contracting.CORPORATE GOVERNANCEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCESECURITY HOLDER2052770AGAINST205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Shareholder proposal regarding a report on healthcare coverage gaps.CORPORATE GOVERNANCEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCESECURITY HOLDER2052770AGAINST205277FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Shareholder proposal regarding a report on political contributions.OTHER SOCIAL ISSUESSECURITY HOLDER2052770AGAINST205277FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Back-End Transactions - (1) To enter into a statutory merger under Dutch law pursuant to which Merus, as disappearing company, will merge with and into New Topco, as surviving company, and (2) to approve, within the meaning of Section 2:107a of the Dutch Civil Code and to the extent required by applicable law, such statutory merger and the subsequent cancellation of all class A shares in the capital of New Topco with repayment and distribution by New Topco of an amount per class A share so cancelled equal to the Offer Consideration, without interest and subject to any applicable withholding taxesEXTRAORDINARY TRANSACTIONSISSUER182740FOR18274FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Back-End Transactions - (1) to amend Menus' Articles of Association to increase Merus' authorized share capital in one or more tranches, and (2) to convert Merus N.V. into a private company with limited liability, promptly following the delisting of Merus' common shares from the Nasdaq Global Market and to amend Menus' Articles of Association accordinglyCORPORATE GOVERNANCEISSUER182740FOR18274FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Effective upon the acceptance for payment by Purchaser for all Common Shares validly tendered and not properly withdrawn pursuant to the Offer prior to the Expiration Time, to provide full and final discharge to each member of the Merus Board for their acts of management or supervision, as applicable, up to and including the date of the EGM to the fullest extent permitted under applicable lawDIRECTOR ELECTIONSISSUER182740FOR18274FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Greg Mueller as non-executive director of Merus - Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non- executive directorCORPORATE GOVERNANCEISSUER182740FOR18274NONE19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Greg Mueller as non-executive director of Merus - Appointment of Greg Mueller as non-executive director of Merus Greg MuellerDIRECTOR ELECTIONSISSUER182740FOR18274FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Anthony Pagano as non-executive director of Merus - Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non- executive directorCORPORATE GOVERNANCEISSUER182740FOR18274NONE19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Anthony Pagano as non-executive director of Merus - Appointment of Anthony Pagano as non-executive director of Merus Anthony PaganoDIRECTOR ELECTIONSISSUER182740FOR18274FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Martine van Vugt, Ph.D., as non-executive director of Merus - Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non- executive directorCORPORATE GOVERNANCEISSUER182740FOR18274NONE19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Martine van Vugt, Ph.D., as non-executive director of Merus - Appointment of Martine van Vugt, Ph.D., as non-executive director of Merus Martine van Vugt, Ph.D.DIRECTOR ELECTIONSISSUER182740FOR18274FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Non-binding advisory proposal to approve certain compensation arrangementsSECTION 14A SAY-ON-PAY VOTESISSUER182740FOR18274FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Election of Directors Roland DiggelmannDIRECTOR ELECTIONSISSUER3950FOR395FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Election of Directors Domitille Doat-Le BigotDIRECTOR ELECTIONSISSUER3950FOR395FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Election of Directors Elisha W. FinneyDIRECTOR ELECTIONSISSUER3950FOR395FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Election of Directors Pablo PerversiDIRECTOR ELECTIONSISSUER3950FOR395FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Election of Directors Thomas P. SaliceDIRECTOR ELECTIONSISSUER3950FOR395FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Election of Directors Brian ShepherdDIRECTOR ELECTIONSISSUER3950FOR395FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Election of Directors Michael J. TokichDIRECTOR ELECTIONSISSUER3950FOR395FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Election of Directors Wolfgang WienandDIRECTOR ELECTIONSISSUER3950FOR395FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Election of Directors Ingrid ZhangDIRECTOR ELECTIONSISSUER3950FOR395FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Ratification of Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER3950FOR395FOR19 METTLER-TOLEDO INTERNATIONAL INC.592688105US592688105405/07/2026Advisory Vote to Approve Executive CompensationSECTION 14A SAY-ON-PAY VOTESISSUER3950FOR395FOR19 MODERNA, INC.60770K107US60770K107911/12/2025To approve a one-time stock option exchange program for non-Executive Committee employees of Moderna, Inc. (the "Option Exchange Proposal").COMPENSATIONISSUER325420FOR32542FOR19 MODERNA, INC.60770K107US60770K107911/12/2025To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Option Exchange Proposal (the "Adjournment Proposal").CORPORATE GOVERNANCEISSUER325420FOR32542FOR19 MODERNA, INC.60770K107US60770K107905/06/2026To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified or such director's earlier death, resignation or removal. Sandra Horning, M.D.DIRECTOR ELECTIONSISSUER488520AGAINST48852AGAINST19 MODERNA, INC.60770K107US60770K107905/06/2026To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified or such director's earlier death, resignation or removal. Abbas HussainDIRECTOR ELECTIONSISSUER488520FOR48852FOR19 MODERNA, INC.60770K107US60770K107905/06/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER488520AGAINST48852AGAINST19 MODERNA, INC.60770K107US60770K107905/06/2026To approve, on a non-binding, advisory basis, the frequency of future non-binding advisory votes to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4885201 YEAR48852FOR19 MODERNA, INC.60770K107US60770K107905/06/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER488520FOR48852FOR19 MONTE ROSA THERAPEUTICS, INC.61225M102US61225M102706/11/2026To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; Andrew Schiff, M.D.DIRECTOR ELECTIONSISSUER279540FOR27954FOR19 MONTE ROSA THERAPEUTICS, INC.61225M102US61225M102706/11/2026To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; Chandra P. Leo, M.D.DIRECTOR ELECTIONSISSUER279540FOR27954FOR19 MONTE ROSA THERAPEUTICS, INC.61225M102US61225M102706/11/2026To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; Anthony Manning, Ph.D.DIRECTOR ELECTIONSISSUER279540FOR27954FOR19 MONTE ROSA THERAPEUTICS, INC.61225M102US61225M102706/11/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER279540FOR27954FOR19 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Election of the Class I director nominee to serve until the 2029 Annual General Meeting of Shareholders and until his successor is duly elected and qualified. Spike LoyDIRECTOR ELECTIONSISSUER142990FOR14299FOR19 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER142990FOR14299FOR19 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER142990FOR14299FOR19 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Approval of an amendment and restatement of the Company's 2022 Equity Incentive Plan.COMPENSATIONISSUER142990FOR14299FOR19 NATERA, INC.632307104US632307104206/11/2026DIRECTOR: Rowan Chapman*DIRECTOR ELECTIONSISSUER41110FOR4111FOR19 NATERA, INC.632307104US632307104206/11/2026DIRECTOR: Herm Rosenman*DIRECTOR ELECTIONSISSUER41110FOR4111FOR19 NATERA, INC.632307104US632307104206/11/2026DIRECTOR: Jonathan Sheena*DIRECTOR ELECTIONSISSUER41110FOR4111FOR19 NATERA, INC.632307104US632307104206/11/2026DIRECTOR: Eric H. Rubin#DIRECTOR ELECTIONSISSUER41110FOR4111FOR19 NATERA, INC.632307104US632307104206/11/2026To ratify the appointment of Ernst & Young LLP as Natera, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER41110FOR4111FOR19 NATERA, INC.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER41110FOR4111FOR19 NATERA, INC.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER411101 YEAR4111FOR19 NATERA, INC.632307104US632307104206/11/2026To approve an amendment to Natera's 2015 Equity Incentive Plan, as amended and restated.COMPENSATIONISSUER41110FOR4111FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026DIRECTOR: Kevin C. Gorman, Ph.D.DIRECTOR ELECTIONSISSUER67930FOR6793FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026DIRECTOR: Gary A. LyonsDIRECTOR ELECTIONSISSUER67930FOR6793FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026DIRECTOR: Johanna MercierDIRECTOR ELECTIONSISSUER67930FOR6793FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026Advisory vote on the compensation paid to the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER67930FOR6793FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026To approve an amendment of the Company's 2025 Equity Incentive Plan to increase the aggregate number of shares of common stock reserved for issuance thereunder by 4,000,000 shares; andCOMPENSATIONISSUER67930FOR6793FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER67930FOR6793FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Approval of the operating and financial review of Novartis AG, the financial statements of Novartis AG and the consolidated financial statements for the 2025 financial yearCORPORATE GOVERNANCEISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Advisory vote on the report on nonfinancial matters for the 2025 financial yearOTHER SOCIAL ISSUESISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Discharge from liability of the members of the Board of Directors and the Executive CommitteeDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Appropriation of available earnings of Novartis AG as per balance sheet and declaration of dividend for 2025CAPITAL STRUCTUREISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Reduction of share capitalCAPITAL STRUCTUREISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Binding vote on the maximum aggregate amount of compensation for the Board of Directors from the 2026 Annual General Meeting to the 2027 Annual General MeetingCOMPENSATIONISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Binding vote on the maximum aggregate amount of compensation for the Executive Committee for the 2027 financial yearCOMPENSATIONISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Advisory vote on the 2025 Compensation ReportSECTION 14A SAY-ON-PAY VOTESISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Giovanni Caforio as member and Board ChairDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Board of Director: Nancy C. AndrewsDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Board of Director: Ton BuechnerDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Board of Director: Patrice BulaDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Board of Director: Elizabeth DohertyDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Board of Director: Bridgette HellerDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Board of Director: Frans van HoutenDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Board of Director: Elizabeth McNallyDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Board of Director: Simon MoroneyDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Board of Director: Ana de Pro GonzaloDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of Board of Director: John D. YoungDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Election of Board of Director: Charles SwantonDIRECTOR ELECTIONSISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election to the Compensation Committee: Patrice BulaCORPORATE GOVERNANCEISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election to the Compensation Committee: Bridgette HellerCORPORATE GOVERNANCEISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election to the Compensation Committee: Simon MoroneyCORPORATE GOVERNANCEISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election to the Compensation Committee: John D. YoungCORPORATE GOVERNANCEISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Election to the Compensation Committee: Elizabeth McNallyCORPORATE GOVERNANCEISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of the auditorAUDIT-RELATEDISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026Re-election of the Independent ProxyCORPORATE GOVERNANCEISSUER218100FOR21810FOR19 NOVARTIS AG66987V109US66987V109803/06/2026General instructions in case of unannounced motions relating to items on the agenda and on new items on the agenda in accordance with Art. 704b of the Swiss Code of Obligations.CORPORATE GOVERNANCEISSUER218100ABSTAIN21810AGAINST19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Asaf DanzigerDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors William DoyleDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Jeryl HillemanDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors David HungDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Frank LeonardDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Kinyip Gabriel LeungDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Martin MaddenDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Allyson OceanDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Timothy ScannellDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Kristin StaffordDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors William VernonDIRECTOR ELECTIONSISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026The approval and ratification of the appointment, by the Audit Committee of our Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the Company's fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026A non-binding advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER499470FOR49947FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026The approval of our amended and restated 2024 Omnibus Incentive Plan.COMPENSATIONISSUER499470AGAINST49947AGAINST19 NUVALENT, INC.670703107US670703107506/16/2026Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D.DIRECTOR ELECTIONSISSUER286180FOR28618FOR19 NUVALENT, INC.670703107US670703107506/16/2026Election of the following nominees as Class II directors: Ron SquarerDIRECTOR ELECTIONSISSUER286180FOR28618FOR19 NUVALENT, INC.670703107US670703107506/16/2026To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER286180FOR28618FOR19 NUVALENT, INC.670703107US670703107506/16/2026To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER286180FOR28618FOR19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026DIRECTOR: Pravin U. Dugel, M.D.DIRECTOR ELECTIONSISSUER226450FOR22645FOR19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026DIRECTOR: Merilee RainesDIRECTOR ELECTIONSISSUER226450FOR22645FOR19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To approve an advisory vote on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER226450AGAINST22645AGAINST19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2264501 YEAR22645FOR19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 10,000,000 shares.COMPENSATIONISSUER226450FOR22645FOR19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER226450FOR22645FOR19 ORCHESTRA BIOMED HOLDINGS, INC.68572M106US68572M106206/23/2026Election of Class III Directors David HochmanDIRECTOR ELECTIONSISSUER176350FOR17635FOR19 ORCHESTRA BIOMED HOLDINGS, INC.68572M106US68572M106206/23/2026Election of Class III Directors Darren ShermanDIRECTOR ELECTIONSISSUER176350FOR17635FOR19 ORCHESTRA BIOMED HOLDINGS, INC.68572M106US68572M106206/23/2026Election of Class III Directors Eric FainDIRECTOR ELECTIONSISSUER176350WITHHOLD17635AGAINST19 ORCHESTRA BIOMED HOLDINGS, INC.68572M106US68572M106206/23/2026Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER176350FOR17635FOR19 ORCHESTRA BIOMED HOLDINGS, INC.68572M106US68572M106206/23/2026Approval of the Orchestra BioMed Holdings, Inc. 2026 Employee Stock Purchase Plan.COMPENSATIONISSUER176350FOR17635FOR19 ORCHESTRA BIOMED HOLDINGS, INC.68572M106US68572M106206/23/2026Adoption of an advisory (non-binding) resolution approving the compensation of our ''named executive officers''.SECTION 14A SAY-ON-PAY VOTESISSUER176350FOR17635FOR19 ORCHESTRA BIOMED HOLDINGS, INC.68572M106US68572M106206/23/2026Advisory (non-binding) vote on the frequency of future advisory (non-binding) votes on the compensation of our ''named executive officers''.SECTION 14A SAY-ON-PAY VOTESISSUER1763501 YEAR17635FOR19 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026DIRECTOR: Lawrence KleinDIRECTOR ELECTIONSISSUER159860FOR15986FOR19 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026DIRECTOR: Chris MartinDIRECTOR ELECTIONSISSUER159860FOR15986FOR19 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Oruka Therapeutics, Inc. for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER159860FOR15986FOR19 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER159860FOR15986FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Election of three director nominees to serve as Class III directors whose term will expire in 2029. George M. JenkinsDIRECTOR ELECTIONSISSUER44800FOR4480FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Election of three director nominees to serve as Class III directors whose term will expire in 2029. Todd C. DavisDIRECTOR ELECTIONSISSUER44800FOR4480FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Election of three director nominees to serve as Class III directors whose term will expire in 2029. John Doux, M.D.DIRECTOR ELECTIONSISSUER44800FOR4480FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Ratification of the appointment of Ernst & Young as the Company's independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER44800FOR4480FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER44800FOR4480FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER448001 YEAR4480FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval of an amendment to the 2024 Equity Incentive Plan to increase the authorized shares issuable under the 2024 Plan by 750,000 shares.COMPENSATIONISSUER44800FOR4480FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5.CORPORATE GOVERNANCEISSUER44800FOR4480FOR19 PENUMBRA, INC.70975L107US70975L107005/06/2026To approve and adopt the Merger Agreement;EXTRAORDINARY TRANSACTIONSISSUER116060FOR11606FOR19 PENUMBRA, INC.70975L107US70975L107005/06/2026To approve, on a non-binding, advisory basis, the compensation that Penumbra's named executive officers will or may be eligible to receive in connection with the Merger; andSECTION 14A SAY-ON-PAY VOTESISSUER116060FOR11606FOR19 PENUMBRA, INC.70975L107US70975L107005/06/2026To adjourn or postpone the Special Meeting, if necessary or appropriate, to solicit additional proxies if, immediately prior to such adjournment or postponement, there are not sufficient votes to approve the Merger Proposal or to ensure that any supplement or amendment to the accompanying proxy statement/prospectus is timely provided to Penumbra Stockholders.CORPORATE GOVERNANCEISSUER116060FOR11606FOR19 PENUMBRA, INC.70975L107US70975L107006/18/2026DIRECTOR: Arani Bose, M.D.DIRECTOR ELECTIONSISSUER116060ABSTAIN11606AGAINST19 PENUMBRA, INC.70975L107US70975L107006/18/2026DIRECTOR: Bridget O'RourkeDIRECTOR ELECTIONSISSUER116060FOR11606FOR19 PENUMBRA, INC.70975L107US70975L107006/18/2026DIRECTOR: Surbhi SarnaDIRECTOR ELECTIONSISSUER116060FOR11606FOR19 PENUMBRA, INC.70975L107US70975L107006/18/2026To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Penumbra, Inc. for the fiscal year ending December 31, 2026; andAUDIT-RELATEDISSUER116060FOR11606FOR19 PENUMBRA, INC.70975L107US70975L107006/18/2026To approve, on an advisory basis, the compensation of Penumbra, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER116060FOR11606FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Ronald E. BlaylockDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Albert BourlaDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Mortimer J. BuckleyDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Susan Desmond-HellmannDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Joseph J. EchevarriaDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Scott GottliebDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Dan R. LittmanDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Shantanu NarayenDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Suzanne Nora JohnsonDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: James QuinceyDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: James C. SmithDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Cyrus TaraporevalaDIRECTOR ELECTIONSISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Ratify the selection of KPMG LLP as our independent registered public accounting firm for 2026AUDIT-RELATEDISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Approval of the Pfizer Inc. 2019 Stock Plan, as amended April 2026COMPENSATIONISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/20262026 advisory approval of executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1037340FOR103734FOR19 PFIZER INC.717081103US717081103504/23/2026Adopt an Independent Chair PolicyCORPORATE GOVERNANCESECURITY HOLDER1037340AGAINST103734FOR19 PROTAGONIST THERAPEUTICS, INC.74366E102US74366E102906/17/2026DIRECTOR: Dinesh V. Patel, Ph.D.DIRECTOR ELECTIONSISSUER320580FOR32058FOR19 PROTAGONIST THERAPEUTICS, INC.74366E102US74366E102906/17/2026DIRECTOR: L.T. Williams, MD, PhDDIRECTOR ELECTIONSISSUER320580ABSTAIN32058AGAINST19 PROTAGONIST THERAPEUTICS, INC.74366E102US74366E102906/17/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER320580FOR32058FOR19 PROTAGONIST THERAPEUTICS, INC.74366E102US74366E102906/17/2026To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER320580FOR32058FOR19 PROTAGONIST THERAPEUTICS, INC.74366E102US74366E102906/17/2026To approve the adoption of the Company's 2026 Equity Incentive Plan.COMPENSATIONISSUER320580FOR32058FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026DIRECTOR: Jessica ChutterDIRECTOR ELECTIONSISSUER43290FOR4329FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026DIRECTOR: M.B. Klein, MD MS, FACSDIRECTOR ELECTIONSISSUER43290FOR4329FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026DIRECTOR: Stephanie S. Okey, M.S.DIRECTOR ELECTIONSISSUER43290FOR4329FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026DIRECTOR: J.B. Zeldis, M.D., PhDDIRECTOR ELECTIONSISSUER43290FOR4329FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER43290FOR4329FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER43290FOR4329FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors Robert B. CarterDIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors James E. DavisDIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors Luis A. Diaz, Jr., M.D.DIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors Tracey C. DoiDIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors Vicky B. GreggDIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors Wright L. Lassiter IIIDIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors Timothy L. MainDIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors Denise M. MorrisonDIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors Gary M. PfeifferDIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors Timothy M. RingDIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Election of Directors Timothy C. WentworthDIRECTOR ELECTIONSISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026An advisory resolution to approve the executive officer compensation disclosed in the Company's 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Ratification of the appointment of our independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER74630FOR7463FOR19 QUEST DIAGNOSTICS INCORPORATED74834L100US74834L100805/20/2026Stockholder proposal regarding an independent board chairman, if properly presented at the Annual Meeting.CORPORATE GOVERNANCESECURITY HOLDER74630AGAINST7463FOR19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: Howard G. Berger, M.D.DIRECTOR ELECTIONSISSUER57853700FOR5785FOR19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: A. Gregory Sorensen M.DDIRECTOR ELECTIONSISSUER57853700FOR5785FOR19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: Laura P. JacobsDIRECTOR ELECTIONSISSUER57853700ABSTAIN5785AGAINST19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: Lawrence L. LevittDIRECTOR ELECTIONSISSUER57853700FOR5785FOR19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: Gregory E. SpurlockDIRECTOR ELECTIONSISSUER57853700FOR5785FOR19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: David L. SwartzDIRECTOR ELECTIONSISSUER57853700FOR5785FOR19 RADNET, INC.750491102US750491102206/02/2026The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER57853700FOR5785FOR19 RADNET, INC.750491102US750491102206/02/2026An advisory vote to approve the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER57853700FOR5785FOR19 RADNET, INC.750491102US750491102206/02/2026The approval of an amendment and restatement to the Company's Equity Incentive Plan.COMPENSATIONISSUER57853700FOR5785FOR19 REGENERON PHARMACEUTICALS, INC.75886F107US75886F107506/12/2026Election of Directors Joseph L. Goldstein, M.D.DIRECTOR ELECTIONSISSUER77120FOR7712FOR19 REGENERON PHARMACEUTICALS, INC.75886F107US75886F107506/12/2026Election of Directors Christine A. PoonDIRECTOR ELECTIONSISSUER77120FOR7712FOR19 REGENERON PHARMACEUTICALS, INC.75886F107US75886F107506/12/2026Election of Directors David P. Schenkein, M.D.DIRECTOR ELECTIONSISSUER77120FOR7712FOR19 REGENERON PHARMACEUTICALS, INC.75886F107US75886F107506/12/2026Election of Directors Craig B. Thompson, M.D.DIRECTOR ELECTIONSISSUER77120FOR7712FOR19 REGENERON PHARMACEUTICALS, INC.75886F107US75886F107506/12/2026Election of Directors Huda Y. Zoghbi, M.D.DIRECTOR ELECTIONSISSUER77120FOR7712FOR19 REGENERON PHARMACEUTICALS, INC.75886F107US75886F107506/12/2026Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER77120FOR7712FOR19 REGENERON PHARMACEUTICALS, INC.75886F107US75886F107506/12/2026Proposal to approve, on an advisory basis, compensation of the Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER77120FOR7712FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026DIRECTOR: Jean Bennett, M.D., PhDDIRECTOR ELECTIONSISSUER184150FOR18415FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026DIRECTOR: A.N. Karabelas, Ph.D.DIRECTOR ELECTIONSISSUER184150FOR18415FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026DIRECTOR: Daniel TasséDIRECTOR ELECTIONSISSUER184150FOR18415FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026To ratify the appointment of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER184150FOR18415FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026Advisory vote on the compensation paid to the Company's executive employees.SECTION 14A SAY-ON-PAY VOTESISSUER184150FOR18415FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026To approve a stock option exchange for our non-executive employees.COMPENSATIONISSUER184150FOR18415FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026To approve a stock option exchange for our executive employees.COMPENSATIONISSUER184150AGAINST18415AGAINST19 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal; Douglas S. IngramDIRECTOR ELECTIONSISSUER195680FOR19568FOR19 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal; Claire Mazumdar, Ph.D.DIRECTOR ELECTIONSISSUER195680FOR19568FOR19 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER195680FOR19568FOR19 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER195680FOR19568FOR19 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To approve an amendment to our Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 300,000,000 to 450,000,000;CAPITAL STRUCTUREISSUER195680FOR19568FOR19 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026DIRECTOR: Alexis BorisyDIRECTOR ELECTIONSISSUER321010FOR32101FOR19 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026DIRECTOR: Mark A Goldsmith MD PhDDIRECTOR ELECTIONSISSUER321010FOR32101FOR19 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; andAUDIT-RELATEDISSUER321010FOR32101FOR19 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER321010FOR32101FOR19 RHYTHM PHARMACEUTICALS, INC.76243J105US76243J105106/24/2026DIRECTOR: David W.J. McGirrDIRECTOR ELECTIONSISSUER467990FOR46799FOR19 RHYTHM PHARMACEUTICALS, INC.76243J105US76243J105106/24/2026DIRECTOR: David P. Meeker, M.D.DIRECTOR ELECTIONSISSUER467990FOR46799FOR19 RHYTHM PHARMACEUTICALS, INC.76243J105US76243J105106/24/2026Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER467990FOR46799FOR19 RHYTHM PHARMACEUTICALS, INC.76243J105US76243J105106/24/2026Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER467990FOR46799FOR19 ROIVANT SCIENCES LTD.G76279101BMG76279101709/10/2025DIRECTOR: Matthew GlineDIRECTOR ELECTIONSISSUER604560FOR60456FOR19 ROIVANT SCIENCES LTD.G76279101BMG76279101709/10/2025DIRECTOR: Keith ManchesterDIRECTOR ELECTIONSISSUER604560FOR60456FOR19 ROIVANT SCIENCES LTD.G76279101BMG76279101709/10/2025DIRECTOR: Melissa EpperlyDIRECTOR ELECTIONSISSUER604560FOR60456FOR19 ROIVANT SCIENCES LTD.G76279101BMG76279101709/10/2025To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Roivant's independent registered public accounting firm for Roivant's fiscal year ending March 31, 2026, to appoint Ernst & Young LLP as auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for Roivant's fiscal year ending March 31, 2026, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as Roivant's auditor for Roivant's fiscal year ending March 31, 2026.AUDIT-RELATEDCOMPENSATIONISSUER604560FOR60456FOR19 ROIVANT SCIENCES LTD.G76279101BMG76279101709/10/2025To cast a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER604560FOR60456FOR19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026DIRECTOR: David HallalDIRECTOR ELECTIONSISSUER197640FOR19764FOR19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026DIRECTOR: Kristina BurowDIRECTOR ELECTIONSISSUER197640FOR19764FOR19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026DIRECTOR: Michael GilmanDIRECTOR ELECTIONSISSUER197640ABSTAIN19764AGAINST19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026DIRECTOR: Katie PengDIRECTOR ELECTIONSISSUER197640FOR19764FOR19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER197640FOR19764FOR19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER197640AGAINST19764AGAINST19 STERIS PLCG8473T100IE00BFY8C75407/31/2025Election of Directors Dr. Esther M. AlegriaDIRECTOR ELECTIONSISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025Election of Directors Richard C. BreedenDIRECTOR ELECTIONSISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025Election of Directors Daniel A. CarestioDIRECTOR ELECTIONSISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025Election of Directors Cynthia L. FeldmannDIRECTOR ELECTIONSISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025Election of Directors Christopher S. HollandDIRECTOR ELECTIONSISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025Election of Directors Paul E. MartinDIRECTOR ELECTIONSISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025Election of Directors Dr. Nirav R. ShahDIRECTOR ELECTIONSISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025Election of Directors Louis A. ShapiroDIRECTOR ELECTIONSISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025Election of Directors Dr. Mohsen M. SohiDIRECTOR ELECTIONSISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025Election of Directors Dr. Richard M. SteevesDIRECTOR ELECTIONSISSUER57270ABSTAIN5727AGAINST19 STERIS PLCG8473T100IE00BFY8C75407/31/2025To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending March 31, 2026.AUDIT-RELATEDISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025To appoint Ernst & Young Chartered Accountants as the Company's statutory auditor under Irish law to hold office until the conclusion of the Company's next annual general meeting.AUDIT-RELATEDISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025To authorize the Board of Directors of the Company or the Audit Committee of the Board of Directors to determine the remuneration of Ernst & Young Chartered Accountants as the Company's statutory auditor under Irish law.AUDIT-RELATEDCOMPENSATIONISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed pursuant to the disclosure rules of the U.S. Securities and Exchange Commission, including the compensation discussion and analysis and the tabular and narrative disclosure contained in the Company's proxy statement dated June 12, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025To approve a proposal renewing the Board of Directors' authority to issue shares under Irish law.CAPITAL STRUCTUREISSUER57270FOR5727FOR19 STERIS PLCG8473T100IE00BFY8C75407/31/2025To approve a proposal renewing the Board of Directors' authority to opt-out of statutory pre-emption rights under Irish law.CAPITAL STRUCTUREISSUER57270FOR5727FOR19 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026DIRECTOR: G. Clare Kahn, Ph.D.DIRECTOR ELECTIONSISSUER410950FOR41095FOR19 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026DIRECTOR: Adrian Krainer, Ph.D.DIRECTOR ELECTIONSISSUER410950ABSTAIN41095AGAINST19 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026DIRECTOR: Julie Anne SmithDIRECTOR ELECTIONSISSUER410950FOR41095FOR19 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER410950FOR41095FOR19 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER410950FOR41095FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Election of Directors. Mary K. BrainerdDIRECTOR ELECTIONSISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Election of Directors. Giovanni Caforio, M.D.DIRECTOR ELECTIONSISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Election of Directors. Kevin A. LoboDIRECTOR ELECTIONSISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Election of Directors. Emmanuel P. MacedaDIRECTOR ELECTIONSISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Election of Directors. Sherilyn S. McCoyDIRECTOR ELECTIONSISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Election of Directors. Rachel M. RuggeriDIRECTOR ELECTIONSISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Election of Directors. Andrew K. SilvernailDIRECTOR ELECTIONSISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Election of Directors. Lisa M. Skeete TatumDIRECTOR ELECTIONSISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Election of Directors. Ronda E. StrykerDIRECTOR ELECTIONSISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Election of Directors. Rajeev SuriDIRECTOR ELECTIONSISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2026.AUDIT-RELATEDISSUER296280FOR29628FOR19 STRYKER CORPORATION863667101US863667101305/06/2026Advisory Vote to Approve Named Executive Officer Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER296280FOR29628FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Robert W. DugganDIRECTOR ELECTIONSISSUER4815032000FOR48150FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Mahkam ZanganehDIRECTOR ELECTIONSISSUER4815032000FOR48150FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Manmeet S. SoniDIRECTOR ELECTIONSISSUER4815032000FOR48150FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Kenneth A. ClarkDIRECTOR ELECTIONSISSUER4815032000FOR48150FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Robert BoothDIRECTOR ELECTIONSISSUER4815032000FOR48150FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Alessandra CesanoDIRECTOR ELECTIONSISSUER4815032000FOR48150FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Yu (Michelle) XiaDIRECTOR ELECTIONSISSUER4815032000FOR48150FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Mostafa RonaghiDIRECTOR ELECTIONSISSUER4815032000FOR48150FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Jeff HuberDIRECTOR ELECTIONSISSUER4815032000FOR48150FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026Ratification of the appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER4815032000FOR48150FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026Approval, by a non-binding advisory vote, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4815032000AGAINST48150AGAINST19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to Increase the Number of Shares of Common Stock.COMPENSATIONISSUER4815032000FOR48150FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026Election of Directors Pierre LegaultDIRECTOR ELECTIONSISSUER51650FOR5165FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026Election of Directors Michael A. MetzgerDIRECTOR ELECTIONSISSUER51650FOR5165FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER51650FOR5165FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To ratify the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER51650FOR5165FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve the Syndax Pharmaceuticals, Inc. 2026 Equity Incentive Plan.COMPENSATIONISSUER51650FOR5165FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve the Syndax Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan.COMPENSATIONISSUER51650FOR5165FOR19 TEVA PHARMACEUTICAL INDUSTRIES LIMITED881624209US881624209805/28/2026TO APPOINT DR. SOL J. BARER TO SERVE AS A DIRECTOR UNTIL TEVA'S 2029 ANNUAL MEETING OF SHAREHOLDERS Dr. Sol J. BarerDIRECTOR ELECTIONSISSUER3041070FOR304107FOR19 TEVA PHARMACEUTICAL INDUSTRIES LIMITED881624209US881624209805/28/2026TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE OFFICERSSECTION 14A SAY-ON-PAY VOTESISSUER3041070FOR304107FOR19 TEVA PHARMACEUTICAL INDUSTRIES LIMITED881624209US881624209805/28/2026TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS TEVA'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM UNTIL TEVA'S 2027 ANNUAL MEETING OF SHAREHOLDERSAUDIT-RELATEDISSUER3041070FOR304107FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Election of Directors: Colleen E. JayDIRECTOR ELECTIONSISSUER267470FOR26747FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Election of Directors: Barbara A. CarboneDIRECTOR ELECTIONSISSUER267470FOR26747FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Election of Directors: Lawrence E. KurziusDIRECTOR ELECTIONSISSUER267470FOR26747FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Election of Directors: Cynthia L. LuccheseDIRECTOR ELECTIONSISSUER267470FOR26747FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Election of Directors: Teresa S. MaddenDIRECTOR ELECTIONSISSUER267470FOR26747FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Election of Directors: Maria Rivas, M.D.DIRECTOR ELECTIONSISSUER267470FOR26747FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Election of Directors: Walter M Rosebrough, Jr.DIRECTOR ELECTIONSISSUER267470FOR26747FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Election of Directors: Robert S. WeissDIRECTOR ELECTIONSISSUER267470FOR26747FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Election of Directors: Albert G. White IIIDIRECTOR ELECTIONSISSUER267470FOR26747FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2026.AUDIT-RELATEDISSUER267470FOR26747FOR19 THE COOPER COMPANIES, INC.216648501US216648501904/07/2026Approve, on a non-binding, advisory basis, the compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER267470AGAINST26747AGAINST19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Marc N. CasperDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Nelson J. ChaiDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Ruby R. ChandyDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors C. Martin HarrisDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Tyler JacksDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Jennifer M. JohnsonDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors R. Alexandra KeithDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Karen S. LynchDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Debora L. SparDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Scott M. SperlingDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Dion J. WeislerDIRECTOR ELECTIONSISSUER191230FOR19123FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026An advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER191230AGAINST19123AGAINST19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2026.AUDIT-RELATEDISSUER191230FOR19123FOR19 UCB SAB93562120BE000373953004/30/2026Approve Financial Statements, Allocation of Income, and Dividends of EUR 1.45 per ShareCORPORATE GOVERNANCEISSUER47190FOR4719FOR19 UCB SAB93562120BE000373953004/30/2026Approve Remuneration ReportSECTION 14A SAY-ON-PAY VOTESISSUER47190FOR4719FOR19 UCB SAB93562120BE000373953004/30/2026Approve Discharge of DirectorsDIRECTOR ELECTIONSISSUER47190FOR4719FOR19 UCB SAB93562120BE000373953004/30/2026Approve Discharge of AuditorsAUDIT-RELATEDISSUER47190FOR4719FOR19 UCB SAB93562120BE000373953004/30/2026Reelect Jean-Christophe Tellier as DirectorDIRECTOR ELECTIONSISSUER47190FOR4719FOR19 UCB SAB93562120BE000373953004/30/2026Reelect Cedric van Rijckevorsel as DirectorDIRECTOR ELECTIONSISSUER47190FOR4719FOR19 UCB SAB93562120BE000373953004/30/2026Approve Renewal of Change-of-Control Clause Re: EMTN Program - Art. 7:151 of the BCCACORPORATE GOVERNANCEISSUER47190FOR4719FOR19 UCB SAB93562120BE000373953004/30/2026Renew Authorization to Increase Share Capital within the Framework of Authorized CapitalCAPITAL STRUCTUREISSUER47190FOR4719FOR19 UCB SAB93562120BE000373953004/30/2026Authorize Share Repurchase Program and Reissuance of Repurchased SharesCAPITAL STRUCTUREISSUER47190FOR4719FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Christopher CauseyDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Richard GiltnerDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Ray KurzweilDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Jan MalcolmDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Linda MaxwellDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Nilda MesaDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Judy OlianDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Christopher PatuskyDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Martine RothblattDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Louis SullivanDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Tommy ThompsonDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Kevin TraceyDIRECTOR ELECTIONSISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.COMPENSATIONISSUER49030FOR4903FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER49030FOR4903FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Election of Directors. Charles BakerDIRECTOR ELECTIONSISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Election of Directors. Timothy FlynnDIRECTOR ELECTIONSISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Election of Directors. Paul GarciaDIRECTOR ELECTIONSISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Election of Directors. Kristen GilDIRECTOR ELECTIONSISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Election of Directors. Scott Gottlieb, M.D.DIRECTOR ELECTIONSISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Election of Directors. Stephen HemsleyDIRECTOR ELECTIONSISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Election of Directors. F. William McNabb IIIDIRECTOR ELECTIONSISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Election of Directors. Valerie Montgomery Rice, M.D.DIRECTOR ELECTIONSISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Election of Directors. John Noseworthy, M.D.DIRECTOR ELECTIONSISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Advisory approval of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2026.AUDIT-RELATEDISSUER113340FOR11334FOR19 UNITEDHEALTH GROUP INCORPORATED91324P102US91324P102106/01/2026If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent.CORPORATE GOVERNANCESECURITY HOLDER113340AGAINST11334FOR19 UPSTREAM BIO, INC.91678A107US91678A107906/09/2026DIRECTOR: H. E. Fleming Jr., M.D.DIRECTOR ELECTIONSISSUER300520FOR30052FOR19 UPSTREAM BIO, INC.91678A107US91678A107906/09/2026DIRECTOR: L. Ratcliffe,MBChB, PhDDIRECTOR ELECTIONSISSUER300520FOR30052FOR19 UPSTREAM BIO, INC.91678A107US91678A107906/09/2026To ratify the appointment of PricewaterhouseCoopers LLP as Upstream's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER300520FOR30052FOR19 VAXCYTE, INC.92243G108US92243G108506/15/2026DIRECTOR: Olivier Brandicourt MDDIRECTOR ELECTIONSISSUER130920FOR13092FOR19 VAXCYTE, INC.92243G108US92243G108506/15/2026DIRECTOR: Halley Gilbert, J.D.DIRECTOR ELECTIONSISSUER130920FOR13092FOR19 VAXCYTE, INC.92243G108US92243G108506/15/2026DIRECTOR: Grant E. Pickering MBADIRECTOR ELECTIONSISSUER130920FOR13092FOR19 VAXCYTE, INC.92243G108US92243G108506/15/2026Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER130920FOR13092FOR19 VAXCYTE, INC.92243G108US92243G108506/15/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER130920FOR13092FOR19 VENTYX BIOSCIENCES, INC.92332V107US92332V107003/03/2026To adopt the Agreement and Plan of Merger (as it may be amended from time to time), dated as of January 7, 2026, by and among Eli Lilly and Company, RYLS Merger Corporation ("merger sub"), and Ventyx Biosciences, Inc. (the "merger agreement");EXTRAORDINARY TRANSACTIONSISSUER514500FOR51450FOR19 VENTYX BIOSCIENCES, INC.92332V107US92332V107003/03/2026To approve, on a non-binding, advisory basis, the compensation that will or may become payable by Ventyx Biosciences, Inc. to its named executive officers in connection with the merger of merger sub with and into Ventyx Biosciences, Inc.; andSECTION 14A SAY-ON-PAY VOTESISSUER514500FOR51450FOR19 VENTYX BIOSCIENCES, INC.92332V107US92332V107003/03/2026To adjourn the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting.CORPORATE GOVERNANCEISSUER514500FOR51450FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Sangeeta BhatiaDIRECTOR ELECTIONSISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Lloyd CarneyDIRECTOR ELECTIONSISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Alan GarberDIRECTOR ELECTIONSISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Reshma KewalramaniDIRECTOR ELECTIONSISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Michel LagardeDIRECTOR ELECTIONSISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Jeffrey LeidenDIRECTOR ELECTIONSISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Diana McKenzieDIRECTOR ELECTIONSISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Bruce SachsDIRECTOR ELECTIONSISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Jennifer SchneiderDIRECTOR ELECTIONSISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Nancy ThornberryDIRECTOR ELECTIONSISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Suketu UpadhyayDIRECTOR ELECTIONSISSUER278170ABSTAIN27817AGAINST19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Approval of 2026 Stock and Option Plan.COMPENSATIONISSUER278170FOR27817FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Shareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent.SHAREHOLDER RIGHTS AND DEFENSESSECURITY HOLDER278170AGAINST27817FOR19 VIKING THERAPEUTICS INC92686J106US92686J106005/19/2026DIRECTOR: J. Matthew SingletonDIRECTOR ELECTIONSISSUER369850FOR36985FOR19 VIKING THERAPEUTICS INC92686J106US92686J106005/19/2026DIRECTOR: S. Kathryn Rouan, Ph DDIRECTOR ELECTIONSISSUER369850ABSTAIN36985AGAINST19 VIKING THERAPEUTICS INC92686J106US92686J106005/19/2026TO RATIFY THE SELECTION OF CBIZ CPAS P.C. AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.AUDIT-RELATEDISSUER369850FOR36985FOR19 VIKING THERAPEUTICS INC92686J106US92686J106005/19/2026TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER369850FOR36985FOR19 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified. Tomas KiselakDIRECTOR ELECTIONSISSUER450050FOR45005FOR19 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified. Jennifer K. MosesDIRECTOR ELECTIONSISSUER450050FOR45005FOR19 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER450050FOR45005FOR19 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER450050FOR45005FOR19 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4500501 YEAR45005FOR19 VOR BIOPHARMA INC.929033207US929033207406/11/2026To elect each of the two Class II director nominees set forth in the Proxy Statement to our board of directors, each to serve a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Andrew Levin, M.D., Ph.D.DIRECTOR ELECTIONSISSUER100200FOR10020FOR19 VOR BIOPHARMA INC.929033207US929033207406/11/2026To elect each of the two Class II director nominees set forth in the Proxy Statement to our board of directors, each to serve a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Fouad Namouni, M.D.DIRECTOR ELECTIONSISSUER100200FOR10020FOR19 VOR BIOPHARMA INC.929033207US929033207406/11/2026To approve the amendment and restatement of our Amended and Restated 2021 Equity Incentive Plan.COMPENSATIONISSUER100200AGAINST10020AGAINST19 VOR BIOPHARMA INC.929033207US929033207406/11/2026To ratify the selection by the audit committee of the board of directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER100200FOR10020FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026DIRECTOR: James A. GeraghtyDIRECTOR ELECTIONSISSUER314200FOR31420FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026DIRECTOR: Steven Hyman, M.D.DIRECTOR ELECTIONSISSUER314200FOR31420FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026DIRECTOR: A. Sandrock M.D., Ph.D.DIRECTOR ELECTIONSISSUER314200FOR31420FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER314200FOR31420FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER314200FOR31420FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026To approve an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company's capital stock from 125,000,000 shares to 245,000,000 shares and increase the number of authorized shares of common stock from 120,000,000 shares of common stock to 240,000,000 shares of common stock.CAPITAL STRUCTUREISSUER314200FOR31420FOR19 WATERS CORPORATION941848103US941848103501/27/2026To approve the issuance of shares of common stock, par value $0.01 per share, of the Company (the "Waters Common Stock"), pursuant to the Agreement and Plan of Merger, dated as of July 13, 2025, by and among the Company, Becton, Dickinson and Company, Augusta SpinCo Corporation and Beta Merger Sub, Inc., as amended from time to time (the "Share Issuance Proposal").EXTRAORDINARY TRANSACTIONSISSUER95220FOR9522FOR19 WATERS CORPORATION941848103US941848103501/27/2026Approve adjourning the Special Meeting, if necessary, (a) to solicit additional proxies if there are insufficient votes to approve the Share Issuance Proposal, (b) if insufficient shares of Waters Common Stock are represented (online or by proxy) to conduct business at the Special Meeting, and (c) to allow time to file or mail any supplemental or amended legal disclosures required by law, and to give shareholders sufficient time to receive and review such disclosures before the Special Meeting.CORPORATE GOVERNANCEISSUER95220FOR9522FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Dr. Flemming Ornskov, M.D., M.P.H.DIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Linda BaddourDIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Udit Batra, Ph.D.DIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Dan BrennanDIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Richard FearonDIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Claire M. Fraser, Ph.D.DIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Pearl S. Huang, Ph.D.DIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Wei JiangDIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Heather KnightDIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Christopher A. KueblerDIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Mark VergnanoDIRECTOR ELECTIONSISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; andAUDIT-RELATEDISSUER109270FOR10927FOR19 WATERS CORPORATION941848103US941848103505/21/2026To approve, on a non-binding, advisory basis, the compensation of the Company's executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER109270FOR10927FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Paul B. Bolno, M.D., MBADIRECTOR ELECTIONSISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Mark H. N. Corrigan, M.D.DIRECTOR ELECTIONSISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Christian HenryDIRECTOR ELECTIONSISSUER247270AGAINST24727AGAINST19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Peter Kolchinsky, Ph.D.DIRECTOR ELECTIONSISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Adrian RawcliffeDIRECTOR ELECTIONSISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Ken TakanashiDIRECTOR ELECTIONSISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Aik Na TanDIRECTOR ELECTIONSISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Gregory L. Verdine, Ph.D.DIRECTOR ELECTIONSISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Heidi L. Wagner, J.D.DIRECTOR ELECTIONSISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2025, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP's remuneration for services provided through the date of our 2026 Annual General Meeting of Shareholders.AUDIT-RELATEDCOMPENSATIONISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve our payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis set forth under "Proposal 3: Non-Employee Directors' Compensation" in the proxy statement.COMPENSATIONISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve a proposed amendment to our 2021 Equity Incentive Plan, as amended, in the manner and on the basis as set forth under "Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as amended" in the proxy statement.COMPENSATIONISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd.CAPITAL STRUCTUREISSUER247270AGAINST24727AGAINST19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER247270FOR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2472701 YEAR24727FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471606/22/2026To approve the scheme of arrangement under Singapore law among Wave Life Sciences Ltd., a public company limited by shares incorporated under the laws of the Republic of Singapore ("Wave-Singapore"), the shareholders of Wave-Singapore and Wave Life Sciences, Inc., a Delaware corporation, subject to approval of the High Court of the Republic of Singapore, as set forth in Wave-Singapore's notice of, and proxy statement relating to, the Special Meeting of Wave-Singapore shareholders.CAPITAL STRUCTUREISSUER300900FOR30090FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors Mark A. ButhmanDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors William F. FeeheryDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors Robert F. FrielDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors Eric M. GreenDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors Janet B. HaugenDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors Molly E. JosephDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors Deborah L. V. KellerDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors Myla P. Lai-GoldmanDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors Stephen H. LockhartDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors Douglas A. MichelsDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Election of Directors Paolo PucciDIRECTOR ELECTIONSISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Ratification of the appointment of our independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER53280FOR5328FOR19 WEST PHARMACEUTICAL SERVICES, INC.955306105US955306105505/04/2026Shareholder proposal regarding an independent Board Chair policy.CORPORATE GOVERNANCESECURITY HOLDER53280AGAINST5328FOR19 ZEALAND PHARMA A/SK9898X127DK006025781405/26/2026Elect Camilla Sylvest as New DirectorDIRECTOR ELECTIONSISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781405/26/2026Authorize Editorial Changes to Adopted Resolutions in Connection with Registration with Danish AuthoritiesCORPORATE GOVERNANCEISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026ACCEPT FINANCIAL STATEMENTS AND STATUTORY REPORTSCORPORATE GOVERNANCEISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026APPROVE ALLOCATION OF INCOME AND OMISSION OF DIVIDENDSCAPITAL STRUCTUREISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026REELECT ALF GUNNAR MARTIN NICKLASSON AS DIRECTORDIRECTOR ELECTIONSISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026REELECT KIRSTEN AARUP DREJER AS DIRECTORDIRECTOR ELECTIONSISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026REELECT LEONARD KRUIMER AS DIRECTORDIRECTOR ELECTIONSISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026REELECT ELAINE SULLIVAN AS DIRECTORDIRECTOR ELECTIONSISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026REELECT ENRIQUE CONTERNO AS DIRECTORDIRECTOR ELECTIONSISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026ELECT IRIS LOEW FRIEDRICH AS NEW DIRECTORDIRECTOR ELECTIONSISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026RATIFY PRICEWATERHOUSECOOPERS AS AUDITORSAUDIT-RELATEDISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026AUTHORIZE SHARE REPURCHASE PROGRAMCAPITAL STRUCTUREISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026APPROVE REMUNERATION REPORT (ADVISORY VOTE)SECTION 14A SAY-ON-PAY VOTESISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026APPROVE REMUNERATION OF DIRECTORS IN THE AMOUNT OF DKK 100,000 FOR EACH DIRECTOR, AND 5,000 RSU FOR CHAIR, 1,000 RSU FOR VICE CHAIR AND 1,500 RSU FOR OTHER DIRECTORS; APPROVE REMUNERATION FOR COMMITTEE WORK IN RSUSCOMPENSATIONISSUER71870FOR7187FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026AUTHORIZE EDITORIAL CHANGES TO ADOPTED RESOLUTIONS IN CONNECTION WITH REGISTRATION WITH DANISH AUTHORITIESCORPORATE GOVERNANCEISSUER71870FOR7187FOR19